

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Study protocol: Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032695
Article Type:	Protocol
Date Submitted by the Author:	01-Jul-2019
Complete List of Authors:	<p>Lachmann, Gunnar; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Knaak, Cornelia; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine von Haefen, Clarissa; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Paeschke, Nadine; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Meisel, Christian; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Nyvlt, Peter; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Schuster, Friederike; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Piper, Sophie; Charité Universitätsmedizin Berlin, Institute of Biometry and Clinical Epidemiology Kruppa, Jochen; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany , Institute of Biometry and Clinical Epidemiology Vorderwülbecke, Gerald; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Balzer, Felix; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine La Roseé, Paul; Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Klinik für Innere Medizin II Schenk, Thomas; Universitätsklinikum Jena, Department of Hematology and Oncology Unterwalder, Nadine; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Kölsch, Uwe; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Lachmann, Nils; Charité Universitätsmedizin Berlin, Institute for Transfusion Medicine, H&I Laboratory Akyüz, Levent; Charité Universitätsmedizin Berlin, Institute for Medical Immunology Brunkhorst, Frank; Universitätsklinikum Jena, Center for Clinical Studies, Department of Anesthesiology and Intensive Care Medicine Volk, Hans-Dieter; Charité Universitätsmedizin Berlin, Institute for</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Medical Immunology Keh, Didier; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Spies, Claudia; Charité, Universitaetsmedizin Berlin, Anaesthesiology
Keywords:	Hemophagocytic Lymphohistiocytosis (HLH), Hemophagocytic syndrome (HS), Macrophage activation syndrome (MAS), Sepsis, biomarker, intensive care unit (ICU)



Study protocol: Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)

**Gunnar Lachmann^{1,2}, Cornelia Knaak¹, Clarissa von Haefen¹, Nadine Paeschke¹,
Christian Meisel³, Peter Nyvlt¹, Friederike S. Schuster¹, Sophie K. Piper^{2,4},
Jochen Kruppa^{2,4}, Gerald Vorderwülbecke¹, Felix Balzer¹, Paul La Roseé⁵,
Thomas Schenk⁶, Nadine Unterwalder³, Uwe Kölsch³, Nils Lachmann⁷, Levent
Akyüz⁸, Frank M. Brunkhorst⁹, Hans-Dieter Volk⁸, Didier Keh¹, Claudia Spies¹**

¹Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK),
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz
1, D-13353 Berlin, Germany

²Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, D-10178 Berlin,
Germany

³Department of Immunology, Labor Berlin - Charité Vivantes GmbH, Sylter Strasse 2,
13353 Berlin

⁴Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin,
corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and
Berlin Institute of Health, Charitéplatz 1, D-10117 Berlin, Germany

⁵Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Klinikstraße 11, D-78052
Villingen-Schwenningen, Germany

⁶Department of Hematology and Oncology, Universitätsklinikum Jena,
Am Klinikum 1, D-07747 Jena, Germany

1
2
3 ⁷Institute for Transfusion Medicine, H&I Laboratory, Charité – Universitätsmedizin
4 Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin,
5 and Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany
6
7

8
9 ⁸Institute for Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate
10 Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
11 Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany
12
13

14
15 ⁹Center for Clinical Studies, Department of Anesthesiology and Intensive Care
16 Medicine, Universitätsklinikum Jena, Salvador-Allende-Platz 27, D-07747 Jena,
17 Germany
18
19

20
21
22
23 Corresponding Author:

24 Dr. med. Gunnar Lachmann

25
26 Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK)
27 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
28 Humboldt-Universität zu Berlin, and Berlin Institute of Health
29 Augustenburger Platz 1, D-13353 Berlin, Germany
30
31

32 Phone: +49 30 450 551 002

33 Fax: +49 30 450 551 909

34 Email: gunnar.lachmann@charite.de
35
36
37
38
39
40
41

42 **Word and Element Counts**

43
44 Abstract: 412

45
46 Introduction: 553

47
48 Discussion: 433

49
50 Figures: 1

51
52 Tables: 1
53
54
55
56
57
58
59
60

Abstract

Background: Hemophagocytic Lymphohistiocytosis (HLH) in adults is characterized by toxic immune activation and a sepsis-like syndrome leading to high numbers of undiagnosed cases and mortality rates up to 68%. Early diagnosis and specific immune suppressive treatment is mandatory to avoid fatal outcome. Though, diagnostic criteria (HLH-2004) are adopted from pediatric HLH, and have not been validated in adults. Experimental studies suggest biomarkers to sufficiently diagnose HLH. However, investigation of biomarkers for diagnosis of adult HLH has not been labored, yet.

Methods: The Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients study (HEMICU) aims to estimate the incidence rate of adult HLH among suspected adult intensive care unit (ICU) patients. Screening for HLH will be performed in 16 ICUs of the Charité – Universitätsmedizin Berlin. Inclusion criteria are bicytopenia, hyperferritinemia ($\geq 500 \mu\text{g/L}$), fever, or when HLH is suspected. Over a period of two years, we expect inclusion of about 100 patients with suspected HLH. HLH will be diagnosed if at least 5 HLH-2004 criteria are fulfilled together with an expert review, all other included patients will serve as controls. Secondly, a panel of potential biomarker candidates will be explored. DNA, plasma and serum will be stored in a biobank.

Results: Primary endpoint of the study is the incidence rate of adult HLH among suspected adult patients during ICU stay. Out of a variety of measured biomarkers, this study furthermore aims to find highly potential biomarkers for diagnosis of adult HLH in ICU.

Conclusion: The HEMICU study is the first study to estimate the incidence rate of adult HLH among suspected patients during ICU stay. Furthermore, we aim to

1
2
3 investigate biomarkers for diagnosis of adult HLH in ICU patients. Results of this
4
5 study will contribute to improved recognition and patient outcome of adult HLH in the
6
7 clinical routine.
8
9

10
11
12
13
14
15 **Keywords:** Hemophagocytic Lymphohistiocytosis (HLH), Hemophagocytic syndrome
16
17 (HS), Macrophage activation syndrome (MAS), sepsis, biomarker, intensive care Unit
18
19 (ICU)
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Background

Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory syndrome due to toxic immune activation associated with multiple organ failure and high mortality in intensive care unit (ICU) patients [1-3]. Primary HLH due to genetic causes has been subject of extensive research in pediatric medicine resulting in an advanced understanding of its pathophysiology including identification of underlying genetic defects related to cytotoxic granule exocytosis [4]. However, much less is known about HLH in adults where the secondary form triggered by infections, autoimmune diseases, malignancies or immunosuppressive therapy is more common. Both hereditary primary and reactive secondary HLH are characterized by impaired immune function, i.e. impaired natural-killer (NK) or cytotoxic-T-cell function leading to abnormal activation of cytokine-releasing macrophages and T-cells and finally to an uncontrolled inflammatory condition known as cytokine storm [5].

Currently, diagnosis is based on the HLH-2004 criteria (Table 1) derived from the pediatric HLH-2004 protocol which has not been validated in adult HLH patients [6, 7]. Moreover, diagnosis of HLH in ICU-admitted patients is hampered by its sepsis-like presentation. Clinical features include repetitive fever, hepato- and/or splenomegaly and antibiotic-refractory infections as well as pulmonary and renal involvement with consequent multiple organ failure [7]. Lab findings may reveal cytopenia, hypertriglyceridemia, ferritin $\geq 500 \mu\text{g/L}$, and hypofibrinogenemia. Timely diagnosis is crucial to initiate adequate treatment and thus to improve the prognosis. As demonstrated by Jordan et al. [8], early therapy reduces mortality to 30-35%. However, up to 78% of all HLH cases remain undiagnosed leading to mortality rates as high as 68% [2, 9]. Given the lack of specific diagnostic tests and the established use of invalidated diagnostic criteria in adults, we aim to identify a biomarker panel of high sensitivity and specificity to allow early detection of HLH in critically ill patients.

1
2
3 This biomarker panel might help to differentiate HLH from sepsis between these two
4
5 types of critical illnesses for ICU patients.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods

Design and screening

Over a two-year period, screening of all patients admitted to 16 ICUs of the Charité - Universitätsmedizin Berlin will be performed. As part of the process, electronic patient charts will be screened daily for bicytopenia by an automated script. All patients with bicytopenia are daily searched for HLH-2004 criteria (Table 1), the HScore [10] and suspected HLH by the study team. If the patient is highly suspicious for HLH, patients will be enrolled after informed consent by the patient itself or the legal representative. Immediately after study enrolment and before initiation of specific HLH treatment, whole blood samples will be obtained for all analyses. Additionally, plasma and serum samples as well as DNA will be stored in a biobank (Figure 1). HLH will be diagnosed if at least 5 HLH-2004 criteria are fulfilled and finally be confirmed after a case-by-case review by two HLH experts. The study aims to include at least 100 patients with suspected HLH. Patients in whom HLH is not confirmed will serve as controls.

Table 1. HLH-2004 diagnostic criteria [6]

HLH-2004 diagnostic criteria of which at least 5 must be fulfilled

Ferritin ≥ 500 $\mu\text{g/L}$

Fever (≥ 38.2 $^{\circ}\text{C}$)

Splenomegaly

Cytopenias in ≥ 2 lines (Hemoglobin < 9 g/dL, platelets < 100 /nL, neutrophils < 1.0 /nL)

Hypertriglyceridemia and/or hypofibrinogenemia
(fasting triglycerides ≥ 265 mg/dL, fibrinogen < 1.5 g/L)

Hemophagocytosis in bone marrow or spleen or lymph nodes

1
2
3 Low or absent NK activity

4
5 Soluble CD25 (soluble IL-2 receptor (sIL-2R)) $\geq 2,400$ U/mL
6
7
8

9
10 Study Population and eligibility criteria for patients
11
12

13
14 Inclusion criteria:

- 15
16
- 17 • Intensive care patients of at least 18 years old
 - 18 • Suspected or diagnosed HLH
 - 19 • Eligible to informed consent by the patient itself or the legal representative
- 20
21
22
23
24
25

26
27 Exclusion criteria:

- 28
29
- 30 • Participation in an interventional study
 - 31 • Female patients with pregnancy or breastfeeding
- 32
33
34
35
36
37

38 Setting

39
40 Participating ICU include anesthesiological, surgical, medical, mixed and neurological
41
42 ICUs. In total, 16 ICUs of the Charité – Universitätsmedizin Berlin will contribute
43
44 patients.
45
46
47
48
49
50

51 Objectives and hypotheses

52
53 This study aims to investigate critically ill patients for adult HLH and estimate its
54
55 incidence rate among suspected patients during ICU stay. Secondly, a panel of
56
57 various biomarkers candidates from experimental and pediatric studies will be
58
59 measured to explore diagnostic potential to diagnose HLH in adult ICU-admitted
60

1
2
3 patients. As a result, HLH might be detected earlier leading to an improved outcome.
4
5 Highly sensitive biomarkers may also help to distinguish HLH from sepsis.
6
7
8
9

10 Statistical analyses

11
12 Incidence rate of HLH among suspected adult patient during ICU stay will be
13
14 calculated with 95% confidence intervals. Investigation of potential biomarker will be
15
16 exploratory. Descriptive statistics between patient groups with confirmed HLH and
17
18 controls will incorporate mean and standard deviation or absolute and relative
19
20 frequencies depending on each variable's scale. Uni- and multivariable logistic
21
22 regression models with confirmed HLH diagnosis as outcome will be calculated for
23
24 different combinations of influencing variables and biomarkers. Receiver operator
25
26 characteristic (ROC) analysis will be performed to determine discrimination ability as
27
28 measured by the area under the curve (AUC) for each continuous biomarker.
29
30 Sensitivity and specificity within our patient sample will be given for cut-off points with
31
32 highest Youden index. Highly potential markers are found when sensitivity and
33
34 specificity each reach 90%.
35
36
37
38
39
40
41
42
43

44 Outcome measures

45 Primary Endpoint

- 46 • Incidence rate of adult HLH among suspected patients during ICU stay

47 Secondary Endpoints

- 48 • Identification of highly sensitive and highly specific biomarkers to safely
49 diagnose adult HLH in ICU
- 50 • Therapy of HLH by clinicians
- 51 • ICU and hospital length of stay
- 52 • Mortality and survival after 6 months

- Quality of life questionnaire 36-item short form health survey (SF-36) after 6 months [11]
- Human immunodeficiency virus (HIV) antibodies and -antigen
- Epstein Barr Virus (EBV) and Cytomegalovirus (CMV) viral loads
- Inflammatory markers (ferritin, C-reactive protein (CRP), procalcitonin (PCT), interleukin (IL)-1 β , IL-6, IL-8, IL-10, IL-18, IL-33, tumor necrosis factor (TNF)- α , interferon (IFN)- γ , sCD25, sCD163, presepsin) [12]
- Perforin and CD107a [13]
- Fibrinogen, triglycerides, bilirubin, lactate dehydrogenase (LDH), liver transaminases (ALAT and ASAT)
- Sodium, serum albumin, serum protein electrophoresis
- Detailed immune status (differential blood count, T cells (CD3+), B cells (CD19+), NK cells (CD16+), T helper cells (CD4+), cytotoxic T cells (CD8+), CD4 / CD8 ratio, HLA-DR of CD8+, CD11a of CD8-, CD57 of CD8-, CD28 of CD8+, HLA-DR of monocytes, CD56bright and CD69 of NK cells)
- Glycosylated ferritin [14] and microRNAs (miR-205-5p, miR-194-5p and miR-30c-5p) [15]
- Chemokines CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL11 (Eotaxin), CCL19, CCL20, CXCL1 CXCL8 (IL-8), CXCL10 (IP-10) , CXCL12 (SDF1A) [16]
- HLA Typing
- Biobanking for future research questions (e.g. genetic polymorphisms and gene expression of PRF1, UNC13D, STX11, STXBP2 [7])

Data collection

Data on all outcome measures will be collected prospectively. Further data including patient demographic data, past medical conditions, physicians' reports and routine laboratory results will be abstracted from the hospital's database. For follow-up six months after study inclusion, patients will be contacted either by telephone or by mail as indicated upon enrolment to assess health-related quality of life and mortality, respectively.

Immunological measurements

Plasma concentrations of soluble IL-2R (sCD25) will be determined with the IMMULITE™ semi-automatic chemiluminescent immunoassay (Siemens Healthcare GmbH, Erlangen, Germany). Additional soluble factors IL-1 β , IL-6, IL-8, IL-10, IL-18, IL-33, TNF- α , IFN- γ will be measured by Meso Scale Discovery® (Meso Scale Diagnostics, Maryland USA). The kit provides all reagents, together with a 96-well plate with specific pre-coated spots, the detection antibodies and assay diluent. The standard will be reconstituted with assay diluent to obtain a lot-specific concentration which differs for all cytokines. The vials are inverted multiple times for mixing and, after vortexing, the vials will be kept for 5–10 min at RT and then on ice until use. Preparation of further serial 1:5 dilution of Cytokine Standard is performed. Quality Controls (low and high) are components of the kits and respective Quality Control ranges are provided by the manufacturer. The Quality Controls (low and high) will be reconstituted with 250 μ l of deionized water. The vials are inverted multiple times for mixing and, after vortexing, kept for 5–10 min at RT and then on ice until use. Plasma concentrations of soluble CD163 protein levels from plasma will be determined with the Quantikine® ELISA human CD163 Immunoassay (R&D Systems, Minneapolis, USA). The minimum detectable dose ranged from 0.058-0.613 ng/mL. For measurement of presepsin, Presepsin (Human) ELISA Kit will be used (BioVision, California, USA) with a detection range of 0.156-10 ng/mL.

Flow cytometric analysis of human lymphocyte subsets in EDTA whole blood will be performed, as described recently [17]. Briefly, the following mouse anti-human fluorescently-labelled monoclonal antibodies (mAb) are used for quantification of lymphocyte subsets and analysis of T and NK cell activation markers: cluster of

1
2
3 differentiation (CD)3 Allophycocyanine-Alexa Fluor 750 (APC-A750), CD4 energy
4 coupled dye (ECD), CD8 APC, CD11a Fluorescein isothiocyanate (FITC), CD14
5
6 FITC, CD16 Phycoerythrin (PE), CD19 PE-Cy5.5, CD28 PC5, CD45 Krome-Orange
7
8 (KrO), CD56 PE or CD56 APC, CD57 Pacific Blue (PB), CD69 PE, HLA-DR PE, (all
9
10 from Beckman Coulter). Functional analysis of NK cells will be performed using the
11
12 CD107a degranulation assay according to a protocol published by Bryceson et al.
13
14 [18]. Briefly, peripheral blood mononuclear cells (PBMC) will be isolated by density
15
16 gradient centrifugation and incubated overnight in the presence or absence of 3600
17
18 IU/mL recombinant interleukin-2 (PeproTech). PBMC will then be incubated with the
19
20 target cell line K562 (ATCC) in a 1:1 ratio for 3 hours. Subsequently, CD107a
21
22 expression on NK cells is assessed by staining samples with fluorescently-labelled
23
24 antibodies against lineage markers (see above) and an anti-CD107a FITC-labelled
25
26 mAb (eBioscience). Perforin expression in NK cells will be assessed by intracellular
27
28 staining in unstimulated NK cells using the PerFix-nc reagent (Beckman Coulter) for
29
30 cell permeabilization and an APC-labelled anti-perforin mAb (eBioscience) according
31
32 the manufacturer's instructions.
33
34
35
36
37
38
39

40 Expression of human leukocyte antigen-DR (HLA-DR) on monocytes (mHLA-DR) will
41
42 be determined by flow cytometry using a highly standardized quantitative assay, as
43
44 described earlier [19]. In short, whole blood in Vacutainer tubes (BD Biosciences,
45
46 San Jose, CA, USA) containing EDTA are stained with 20 µl of monoclonal
47
48 phycoerythrin-conjugated anti-HLA-DR and PerCP-Cy5.5-conjugated anti-CD14
49
50 antibodies (Quantibrite HLA-DR/monocyte™; BD Biosciences) in the dark at room
51
52 temperature for 30 min. Erythrocyte lysis will be done with 0.5 ml of lysing solution
53
54 (BD Biosciences) for another 30 min at room temperature. Finally, the cells are
55
56 washed with 1ml PBS buffer containing 2% FCS and analyzed on a Navios flow
57
58 cytometer (Beckman Coulter, Krefeld, Germany). HLA-DR surface expression on
59
60

1
2
3 monocytes will be calculated as monoclonal antibodies bound per cell (mAb/cell)
4
5 using the QuantiBRITE™ PE calibration beads. All flow cytometric analyses will be
6
7 performed on a ten-color Navios flow cytometer using the Navios Software (Beckman
8
9 Coulter). Human glycosylated ferritin will be determined by Enzyme-linked
10
11 Immunosorbent Assay (MyBioSource, San Diego, USA). The sensitivity of this kit is
12
13 2.0 ng/mL.
14
15

16
17 The expression of miR-205-5p, miR-194-5p and miR-30c-5p will be determined in
18
19 whole blood, plasma and serum using a protocol published by Balcells et al. [20].
20
21 Briefly, after RNA isolation, miRNAs are polyadenylated and then reverse transcribed
22
23 with a special primer (RT-primer). For quantitative real time PCR (qPCR), two
24
25 specific primers for each miRNA are designed using a software tool from Busk [21].
26
27 All primers are tested for specificity and efficiency. The qPCR will be performed with
28
29 SYBR Green using the QuantStudio5® (Thermo Fisher, Darmstadt, Germany). The
30
31 quantification of chemokines involved in cell trafficking and effector functions of
32
33 lymphocytes, granulocytes, and mononuclear cells from the CC subfamily (CCL2,
34
35 CCL3, CCL4, CCL5, CCL11, CCL19, and CCL20) as well as the CXC subfamily
36
37 (CXCL1, CXCL8 (IL-8), CXCL10, and CXCL12) will be performed with the
38
39 LUNARIS™ Human 11-Plex Chemokine Kit (AYOXXA Biosystems GmbH, Cologne,
40
41 Germany).
42
43
44
45
46
47

48
49 Determination of human leukocyte antigen (HLA) typing will be performed by reverse
50
51 sequence-specific oligonucleotide (rSSO) assay LABType® (One Lambda, Canoga
52
53 Park, CA, USA). Typing will be assessed on an intermediate resolution level for HLA-
54
55 A, -B, -C, -DRB1, -DQA1 and -DQB1. The assay will be performed according to the
56
57 manufacturer's instructions and data will be acquired on a Luminex® FlexMAP 3D
58
59 machine (Luminex, Austin, TX, USA).
60

Informed consent in critically ill patients

Written informed consent will be obtained from all patients or their legally authorized representatives. Consent for genetic analyzes in future projects will be obtained separately.

Sample size

The true incidence of adult HLH in ICU is unknown. According to our own research [9] and the annual number of patients admitted to our ICU, we expect to see about 200 patients with diagnosed HLH over two years, and about 400 with suspected HLH. Of these, we hope to include at least 100 patients with suspected HLH into the study, of whom about 50 patients are expected to be diagnosed with HLH. When the sample size is 100, a two-sided 95.0% confidence interval for a single proportion using the large sample normal approximation will extend 0.1 from the observed proportion for an expected proportion of 0.5 (nQuery Advisor 7.0).

Ethics

The institutional ethics committee approved this study on August 1, 2018 (EA4/006/18). The data protection commissioner also approved the study (91-SP-18), which was registered with clinicaltrials.gov (NCT03510650) on April 27, 2018.

Discussion

HLH is a rare condition in adults with poor prognosis. Due to the paucity of data available on adult HLH, recognition remains low resulting in delayed diagnosis and

1
2
3 treatment and finally, fatal outcome. This is the first prospective study to
4
5 systematically investigate routine and non-routine parameters for biomarker
6
7 development. Importantly, the daily systematic screening will help to identify HLH
8
9 patients at an early stage of the syndrome which ultimately will improve patient care,
10
11 patients' safety and outcome. Moreover, describing a distinct pattern of biomarkers
12
13 generates new hypothesis for future research thereby potentially providing targets for
14
15 therapy development. With regard to clinical practice, the HEMICU study seeks to
16
17 inform clinicians about HLH and ICU therapies to improve outcomes for HLH
18
19 patients. However, it is of note that this study does not seek to advice the clinician in
20
21 charge to change therapy. No change in routine management is intended due to the
22
23 observational study design and final decisions are left to the discretion of the
24
25 responsible clinician.
26
27
28
29
30
31
32
33

34 Strengths and Limitations

35
36 This study might be limited in that it only includes ICU patients and findings will not
37
38 be generalizable to non-ICU patients. In addition, patients might have developed
39
40 HLH before ICU admission and will thus be detected and measurements obtained at
41
42 an advanced stage of the disease possibly limiting comparability of the results.
43
44 Moreover, we will not assess longitudinal parameters preventing us from describing
45
46 dynamics of biomarkers over time. However, as this study aims to develop a tool
47
48 facilitating diagnosis at the earliest possible time point, study endpoints will not be
49
50 affected by lack of repeated measurements. Possible advances of this study include
51
52 comprehensive lab testing of parameters, which have previously been suggested to
53
54 be associated with HLH [12-16]. Previous studies, most of which are retrospective in
55
56
57
58
59
60

1
2
3 nature, aimed at identifying associations to detect risk factors [2, 22]. Therefore, the
4
5 HEMICU study is the first prospective study of its kind.
6
7
8
9

10 Conclusion

11
12 HLH is a life threatening but poorly investigated condition in adult ICU patients. The
13
14 HEMICU study is the first prospective study in adult ICU patients and aims to
15
16 estimate the incidence rate of adult HLH among suspected patients during ICU stay.
17
18 Furthermore, we aim to investigate biomarkers for diagnosis of adult HLH in ICU
19
20 patients. Results of this study will contribute to improved recognition of adult HLH in
21
22 the clinical routine. Potentially earlier diagnosis and thus more effective treatment of
23
24 adult HLH could lead to improved patient outcome. Moreover, our study will provide a
25
26 better understanding of adult HLH pathophysiology and the biobanking of DNA,
27
28 plasma and serum will generate a data base to investigate future research questions.
29
30
31
32
33
34
35
36
37
38
39

40 Acknowledgements

41 We thank the Department of Cardiovascular Surgery, the Department of Surgery
42
43 CCM/CVK, the Medical Department, Division of Nephrology and Internal Intensive
44
45 Care Medicine (CVK/CCM), the Medical Department, Division of Infectiology and
46
47 Pneumonology, the Medical Department, Division of Cardiology (CVK), the
48
49 Department of Cardiology (CBF), the Department of Neurology with Experimental
50
51 Neurology, and the Department of Anesthesiology and Operative Intensive Care
52
53 Medicine (CBF) for being part of our study and excellent collaboration. We also thank
54
55 the BIH Biobank Core Facility for support, coordination and storage of blood samples
56
57 (biobank). We are grateful to Dr. Kathrin Scholtz for monitoring the study.
58
59
60

Competing interests

The authors declare no conflicts of interest.

References

1. Buyse, S., et al., *Critical care management of patients with hemophagocytic lymphohistiocytosis*. Intensive Care Med, 2010. **36**(10): p. 1695-702.
2. Barba, T., et al., *Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study*. Medicine (Baltimore), 2015. **94**(51): p. e2318.
3. Lachmann, G., et al., *[Hemophagocytic lymphohistiocytosis : A diagnostic challenge on the ICU]*. Anaesthetist, 2016. **65**(10): p. 776-786.
4. Devitt, K., et al., *Hemophagocytic lymphohistiocytosis secondary to T-cell/histiocyte-rich large B-cell lymphoma*. Leuk Res Rep, 2014. **3**(2): p. 42-5.
5. Filipovich, A.H., *Hemophagocytic lymphohistiocytosis (HLH) and related disorders*. Hematology Am Soc Hematol Educ Program, 2009: p. 127-31.
6. Henter, J.I., et al., *HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis*. Pediatr Blood Cancer, 2007. **48**(2): p. 124-31.
7. Ramos-Casals, M., et al., *Adult haemophagocytic syndrome*. Lancet, 2014. **383**(9927): p. 1503-1516.
8. Jordan, M.B., et al., *How I treat hemophagocytic lymphohistiocytosis*. Blood, 2011. **118**(15): p. 4041-52.
9. Lachmann, G., et al., *Hemophagocytic Lymphohistiocytosis: Potentially Underdiagnosed in Intensive Care Units*. Shock, 2018. **50**(2): p. 149-155.
10. Fardet, L., et al., *Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome*. Arthritis Rheumatol, 2014. **66**(9): p. 2613-20.
11. Chrispin, P.S., et al., *Short Form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire*. Anaesthesia, 1997. **52**(1): p. 15-23.
12. Put, K., et al., *Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma*. Rheumatology (Oxford), 2015. **54**(8): p. 1507-17.
13. Rubin, T.S., et al., *Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH*. Blood, 2017. **129**(22): p. 2993-2999.
14. Nabergoj, M., et al., *Diagnostic and prognostic value of low percentage of glycosylated ferritin in acquired hemophagocytic lymphohistiocytosis: A single-center study*. Int J Lab Hematol, 2017. **39**(6): p. 620-624.
15. Bay, A., et al., *Evaluation of the plasma micro RNA expression levels in secondary hemophagocytic lymphohistiocytosis*. Mediterr J Hematol Infect Dis, 2013. **5**(1): p. e2013066.
16. Bracaglia, C., et al., *Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis*. Ann Rheum Dis, 2017. **76**(1): p. 166-172.
17. Klehmet, J., et al., *Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP*. J Neuroimmunol, 2015. **283**: p. 17-22.

- 1
- 2
- 3 18. Bryceson, Y.T., et al., *A prospective evaluation of degranulation assays in the rapid diagnosis*
- 4 *of familial hemophagocytic syndromes*. *Blood*, 2012. **119**(12): p. 2754-63.
- 5 19. Docke, W.D., et al., *Monitoring temporary immunodepression by flow cytometric*
- 6 *measurement of monocytic HLA-DR expression: a multicenter standardized study*. *Clin Chem*,
- 7 2005. **51**(12): p. 2341-7.
- 8 20. Balcells, I., S. Cirera, and P.K. Busk, *Specific and sensitive quantitative RT-PCR of miRNAs with*
- 9 *DNA primers*. *BMC Biotechnol*, 2011. **11**: p. 70.
- 10 21. Busk, P.K., *A tool for design of primers for microRNA-specific quantitative RT-qPCR*. *BMC*
- 11 *Bioinformatics*, 2014. **15**: p. 29.
- 12 22. Ishii, E., et al., *Nationwide survey of hemophagocytic lymphohistiocytosis in Japan*. *Int J*
- 13 *Hematol*, 2007. **86**(1): p. 58-65.
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

Funding

Gunnar Lachmann is participant of the Clinician Scientist Program granted by the Berlin Institute of Health (BIH). The study is supported by the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité – Universitätsmedizin Berlin.

Authors' contributions

Study concept: GL. Conceived and designed the experiments: GL, CvH, NP, CM, PL, TS, NL, HDV, DK. Performing the experiments: GL, CK, CvH, NP, CM, PN, FSS, GV, FB, NU, UK, NL, LA. Analyzing the data: GL, CK, PN, FSS, SKP, JK, PL, TS. Wrote the manuscript: GL, CK, CvH, NP, CM, SKP, NL, LA, DK. Commented on the manuscript: all authors.

Data statement

Due to legal restrictions imposed by the ethics committee of the Charité – Universitätsmedizin Berlin and the data protection commissioner of the Charité – Universitätsmedizin Berlin, public sharing of study data with other researchers or entities is not allowed. Requests may be sent to dai-researchdata@charite.de.

Figure legends

Figure 1. Screening protocol and blood sampling.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

Figure 1 / Screening protocol and blood sampling.

254x190mm (96 x 96 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	14
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	14
Protocol version	#3	Date and version identifier	14
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1

1	Roles and	#5b	Name and contact information for the trial sponsor	16
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	16
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating centre,	16
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	Introduction			
24				
25	Background and	#6a	Description of research question and justification for undertaking	5
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30	Background and	#6b	Explanation for choice of comparators	5
31	rationale: choice of			
32	comparators			
33				
34				
35				
36	Objectives	#7	Specific objectives or hypotheses	5
37				
38	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	Methods:			
46	Participants,			
47	interventions, and			
48	outcomes			
49				
50				
51	Study setting	#9	Description of study settings (eg, community clinic, academic	7
52			hospital) and list of countries where data will be collected.	
53			Reference to where list of study sites can be obtained	
54				
55				
56				
57	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	8
58			eligibility criteria for study centres and individuals who will	
59				
60				

perform the interventions (eg, surgeons, psychotherapists)

1			
2			
3	Interventions:	#11a	Interventions for each group with sufficient detail to allow
4	description		replication, including how and when they will be administered
5			
6	Interventions:	#11b	Criteria for discontinuing or modifying allocated interventions for a
7	modifications		given trial participant (eg, drug dose change in response to harms,
8			participant request, or improving / worsening disease)
9			
10			
11	Interventions:	#11c	Strategies to improve adherence to intervention protocols, and any
12	adherence		procedures for monitoring adherence (eg, drug tablet return;
13			laboratory tests)
14			
15			
16	Interventions:	#11d	Relevant concomitant care and interventions that are permitted or
17	concomitant care		prohibited during the trial
18			
19			
20			
21	Outcomes	#12	Primary, secondary, and other outcomes, including the specific
22			measurement variable (eg, systolic blood pressure), analysis metric
23			(eg, change from baseline, final value, time to event), method of
24			aggregation (eg, median, proportion), and time point for each
25			outcome. Explanation of the clinical relevance of chosen efficacy
26			and harm outcomes is strongly recommended
27			
28			
29			
30	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins
31			and washouts), assessments, and visits for participants. A
32			schematic diagram is highly recommended (see Figure)
33			
34			
35			
36	Sample size	#14	Estimated number of participants needed to achieve study
37			objectives and how it was determined, including clinical and
38			statistical assumptions supporting any sample size calculations
39			
40			
41	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach
42			target sample size
43			
44			

**Methods: Assignment
of interventions (for
controlled trials)**

45			
46			
47			
48			
49			
50	Allocation: sequence	#16a	Method of generating the allocation sequence (eg, computer-
51	generation		generated random numbers), and list of any factors for
52			stratification. To reduce predictability of a random sequence,
53			details of any planned restriction (eg, blocking) should be provided
54			in a separate document that is unavailable to those who enrol
55			participants or assign interventions
56			
57			
58			
59			
60			

1	Allocation concealment	#16b	Mechanism of implementing the allocation sequence (eg, central	7
2	mechanism		telephone; sequentially numbered, opaque, sealed envelopes),	
3			describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7				
8	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	7
9	implementation		participants, and who will assign participants to interventions	
10				
11	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial	7
12			participants, care providers, outcome assessors, data analysts), and	
13			how	
14				
15				
16				
17	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is permissible,	7
18	emergency unblinding		and procedure for revealing a participant's allocated intervention	
19			during the trial	
20				
21				
22	Methods: Data			
23	collection,			
24	management, and			
25	analysis			
26				
27				
28				
29	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other	7
30			trial data, including any related processes to promote data quality	
31			(eg, duplicate measurements, training of assessors) and a	
32			description of study instruments (eg, questionnaires, laboratory	
33			tests) along with their reliability and validity, if known. Reference	
34			to where data collection forms can be found, if not in the protocol	
35				
36				
37				
38				
39	Data collection plan:	#18b	Plans to promote participant retention and complete follow-up,	7
40	retention		including list of any outcome data to be collected for participants	
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	#19	Plans for data entry, coding, security, and storage, including any	7
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of data	
47			management procedures can be found, if not in the protocol	
48				
49				
50				
51	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes.	9
52			Reference to where other details of the statistical analysis plan can	
53			be found, if not in the protocol	
54				
55				
56	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and adjusted	9
57	analyses		analyses)	
58				
59				
60				

1	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	9
2	population and missing		adherence (eg, as randomised analysis), and any statistical methods	
3	data		to handle missing data (eg, multiple imputation)	
4				
5				
6	Methods: Monitoring			
7				
8	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary of its	7
9	formal committee		role and reporting structure; statement of whether it is independent	
10			from the sponsor and competing interests; and reference to where	
11			further details about its charter can be found, if not in the protocol.	
12			Alternatively, an explanation of why a DMC is not needed	
13				
14				
15				
16				
17	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	7
18	interim analysis		including who will have access to these interim results and make	
19			the final decision to terminate the trial	
20				
21				
22	Harms	#22	Plans for collecting, assessing, reporting, and managing solicited	7
23			and spontaneously reported adverse events and other unintended	
24			effects of trial interventions or trial conduct	
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and	7
29			whether the process will be independent from investigators and the	
30			sponsor	
31				
32				
33	Ethics and			
34	dissemination			
35				
36				
37	Research ethics	#24	Plans for seeking research ethics committee / institutional review	14
38	approval		board (REC / IRB) approval	
39				
40				
41	Protocol amendments	#25	Plans for communicating important protocol modifications (eg,	14
42			changes to eligibility criteria, outcomes, analyses) to relevant	
43			parties (eg, investigators, REC / IRBs, trial participants, trial	
44			registries, journals, regulators)	
45				
46				
47	Consent or assent	#26a	Who will obtain informed consent or assent from potential trial	14
48			participants or authorised surrogates, and how (see Item 32)	
49				
50				
51	Consent or assent:	#26b	Additional consent provisions for collection and use of participant	14
52	ancillary studies		data and biological specimens in ancillary studies, if applicable	
53				
54				
55	Confidentiality	#27	How personal information about potential and enrolled participants	14
56			will be collected, shared, and maintained in order to protect	
57			confidentiality before, during, and after the trial	
58				
59				
60				

1	Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
2				
3				
4				
5	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	14
6				
7				
8				
9				
10	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	14
11				
12				
13				
14	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14
15				
16				
17				
18				
19				
20				
21	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	14
22				
23				
24	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	14
25				
26				
27				
28	Appendices			
29				
30				
31	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	14
32				
33				
34	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	14
35				
36				
37				
38				
39				

40 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND
 41 3.0. This checklist was completed on 30. June 2019 using <https://www.goodreports.org/>, a tool made by the
 42 [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU): Prospective Observational Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032695.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Aug-2019
Complete List of Authors:	<p>Lachmann, Gunnar; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Knaak, Cornelia; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine von Haefen, Clarissa; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Paeschke, Nadine; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Meisel, Christian; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Nyvlt, Peter; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Schuster, Friederike; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Piper, Sophie; Charité Universitätsmedizin Berlin, Institute of Biometry and Clinical Epidemiology Kruppa, Jochen; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany , Institute of Biometry and Clinical Epidemiology Vorderwülbecke, Gerald; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Balzer, Felix; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine La Roseé, Paul; Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Klinik für Innere Medizin II Schenk, Thomas; Universitätsklinikum Jena, Department of Hematology and Oncology Unterwalder, Nadine; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Kölsch, Uwe; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Lachmann, Nils; Charité Universitätsmedizin Berlin, Institute for Transfusion Medicine, H&I Laboratory Akyüz, Levent; Charité Universitätsmedizin Berlin, Institute for Medical Immunology Brunkhorst, Frank; Universitätsklinikum Jena, Center for Clinical Studies, Department of Anesthesiology and Intensive Care Medicine Volk, Hans-Dieter; Charité Universitätsmedizin Berlin, Institute for</p>

	Medical Immunology Keh, Didier; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Spies, Claudia; Charité, Universitätsmedizin Berlin, Anaesthesiology
Primary Subject Heading :	Intensive care
Secondary Subject Heading:	Diagnostics, Gastroenterology and hepatology, Haematology (incl blood transfusion), Immunology (including allergy), Rheumatology
Keywords:	Hemophagocytic Lymphohistiocytosis (HLH), Hemophagocytic syndrome (HS), Macrophage activation syndrome (MAS), Sepsis, Biomarker, Intensive Care Unit (ICU)

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU): Prospective Observational Study Protocol

**Gunnar Lachmann^{1,2}, Cornelia Knaak¹, Clarissa von Haefen¹, Nadine Paeschke¹,
Christian Meisel³, Peter Nyvlt¹, Friederike S. Schuster¹, Sophie K. Piper^{2,4},
Jochen Kruppa^{2,4}, Gerald Vorderwülbecke¹, Felix Balzer¹, Paul La Roseé⁵,
Thomas Schenk⁶, Nadine Unterwalder³, Uwe Kölsch³, Nils Lachmann⁷, Levent
Akyüz⁸, Frank M. Brunkhorst⁹, Hans-Dieter Volk⁸, Didier Keh¹, Claudia Spies¹**

¹Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK),
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz
1, D-13353 Berlin, Germany

²Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, D-10178 Berlin,
Germany

³Department of Immunology, Labor Berlin - Charité Vivantes GmbH, Sylter Strasse 2,
13353 Berlin

⁴Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin,
corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and
Berlin Institute of Health, Charitéplatz 1, D-10117 Berlin, Germany

⁵Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Klinikstraße 11, D-78052
Villingen-Schwenningen, Germany

1
2
3 ⁶Department of Hematology and Oncology, Universitätsklinikum Jena,
4 Am Klinikum 1, D-07747 Jena, Germany
5
6

7 ⁷Institute for Transfusion Medicine, H&I Laboratory, Charité – Universitätsmedizin
8 Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin,
9 and Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany
10
11
12

13 ⁸Institute for Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate
14 Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
15 Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany
16
17
18

19 ⁹Center for Clinical Studies, Department of Anesthesiology and Intensive Care
20 Medicine, Universitätsklinikum Jena, Salvador-Allende-Platz 27, D-07747 Jena,
21 Germany
22
23
24
25
26
27

28 Corresponding Author:

29 Dr. med. Gunnar Lachmann

30 Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK)

31 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,

32 Humboldt-Universität zu Berlin, and Berlin Institute of Health

33 Augustenburger Platz 1, D-13353 Berlin, Germany
34
35
36

37 Phone: +49 30 450 551 002

38 Fax: +49 30 450 551 909

39 Email: gunnar.lachmann@charite.de
40
41
42
43
44
45
46

47 **Word and Element Counts**

48 Abstract: 412

49 Introduction: 553

50 Discussion: 433

51 Figures: 1

52 Tables: 1
53
54
55
56
57
58
59
60

Abstract

Introduction: Hemophagocytic Lymphohistiocytosis (HLH) in adults is characterized by toxic immune activation and a sepsis-like syndrome leading to high numbers of undiagnosed cases and mortality rates up to 68%. Early diagnosis and specific immune suppressive treatment is mandatory to avoid fatal outcome. Though, diagnostic criteria (HLH-2004) are adopted from pediatric HLH, and have not been validated in adults. Experimental studies suggest biomarkers to sufficiently diagnose HLH. However, investigation of biomarkers for diagnosis of adult HLH has not been labored, yet.

Methods and analysis: The Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients study (HEMICU) aims to estimate the incidence rate of adult HLH among suspected adult intensive care unit (ICU) patients. Screening for HLH will be performed in 16 ICUs of the Charité – Universitätsmedizin Berlin. Inclusion criteria are bicytopenia, hyperferritinemia ($\geq 500 \mu\text{g/L}$), fever, or when HLH is suspected by the clinicians. Over a period of two years, we expect inclusion of about 100 patients with suspected HLH. HLH will be diagnosed if at least 5 HLH-2004 criteria are fulfilled together with an expert review, all other included patients will serve as controls. Secondly, a panel of potential biomarker candidates will be explored. DNA, plasma and serum will be stored in a biobank. Primary endpoint of the study is the incidence rate of adult HLH among suspected adult patients during ICU stay. Out of a variety of measured biomarkers, this study furthermore aims to find highly potential biomarkers for diagnosis of adult HLH in ICU. Results of this study will contribute to improved recognition and patient outcome of adult HLH in the clinical routine.

1
2
3 *Ethics and dissemination:* The institutional ethics committee approved this study on
4
5 August 1, 2018 (EA4/006/18). Results of the study will be disseminated in an
6
7 international peer-reviewed journal and presented at conferences.
8

9
10 *Trial registration:* The study was registered with clinicaltrials.gov (NCT03510650) on
11
12 April 27, 2018.
13
14

15
16
17 **Keywords:** Hemophagocytic Lymphohistiocytosis (HLH), Hemophagocytic syndrome
18
19 (HS), Macrophage activation syndrome (MAS), sepsis, biomarker, intensive care Unit
20
21 (ICU)
22
23
24
25
26
27

28 **Strengths and Limitations:**

29
30
31 - The HEMICU study is the first prospective study to investigate biomarkers for
32
33 diagnosis of adult HLH in ICU patients.

34
35 - The variety of analyzed biomarkers will provide a better understanding of adult HLH
36
37 pathophysiology.

38
39 - This study aims to investigate critically ill patients for adult HLH and estimate its
40
41 incidence rate among suspected patients during ICU stay.- Biobanking of DNA,
42
43 plasma and serum of adult HLH will generate a database to investigate future
44
45 research questions.

46
47 - This study might be limited in that it only includes ICU patients and findings will not
48
49 be generalizable to non-ICU patients
50
51
52
53
54
55
56
57
58
59
60

Introduction

Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory syndrome due to toxic immune activation associated with multiple organ failure and high mortality in intensive care unit (ICU) patients [1-3]. Primary HLH due to genetic causes has been subject of extensive research in pediatric medicine resulting in an advanced understanding of its pathophysiology including identification of underlying genetic defects related to cytotoxic granule exocytosis [4]. However, much less is known about HLH in adults where the secondary form triggered by infections, autoimmune diseases, malignancies or immunosuppressive therapy is more common. Both hereditary primary and reactive secondary HLH are characterized by impaired immune function, i.e. impaired natural-killer (NK) or cytotoxic-T-cell function leading to abnormal activation of cytokine-releasing macrophages and T-cells and finally to an uncontrolled inflammatory condition known as cytokine storm [5].

Currently, diagnosis is based on the HLH-2004 criteria (Table 1) derived from the pediatric HLH-2004 protocol which has not been validated in adult HLH patients [6, 7]. Moreover, diagnosis of HLH in ICU-admitted patients is hampered by its sepsis-like presentation. Clinical features include repetitive fever, hepato- and/or splenomegaly and antibiotic-refractory infections as well as pulmonary and renal involvement with consequent multiple organ failure [7]. Lab findings may reveal cytopenia, hypertriglyceridemia, ferritin $\geq 500 \mu\text{g/L}$, and hypofibrinogenemia. Timely diagnosis is crucial to initiate adequate treatment and thus to improve the prognosis. As demonstrated by Jordan et al. [8], early therapy reduces mortality to 30-35%. However, up to 78% of all HLH cases remain undiagnosed leading to mortality rates as high as 68% [2, 9]. Given the lack of specific diagnostic tests and the established use of invalidated diagnostic criteria in adults, we aim to identify a biomarker panel of high sensitivity and specificity to allow early detection of HLH in critically ill patients.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods and Analysis

Design and screening

Over a two-year period (ongoing since 01/09/2018), screening of all patients admitted to 16 adult ICUs of the Charité - Universitätsmedizin Berlin will be performed. As part of the process, electronic patient charts will be screened daily for bicytopenia by an automated script. All patients with bicytopenia are daily searched by the study team for HLH-2004 criteria (Table 1), the HScore [10], and suspected HLH by the clinicians. If the patient is highly suspicious for HLH, patients will be enrolled after informed consent by the patient himself or the legal representative. Immediately after study enrolment and before initiation of specific HLH treatment, whole blood samples will be obtained for all analyses. Additionally, plasma and serum samples as well as DNA will be stored in a biobank (Figure 1). HLH will be diagnosed if at least 5 HLH-2004 criteria are fulfilled and finally be confirmed after a case-by-case review by two HLH experts. The study aims to include at least 100 patients with suspected HLH. Patients in whom HLH is not confirmed will serve as controls.

Table 1. HLH-2004 diagnostic criteria [6]

HLH-2004 diagnostic criteria of which at least 5 must be fulfilled
Ferritin ≥ 500 $\mu\text{g/L}$
Fever (≥ 38.2 $^{\circ}\text{C}$)
Splenomegaly
Cytopenias in ≥ 2 lines (Hemoglobin < 9 g/dL , platelets < 100 $/\text{nL}$, neutrophils < 1.0 $/\text{nL}$)
Hypertriglyceridemia and/or hypofibrinogenemia (fasting triglycerides ≥ 265 mg/dL , fibrinogen < 1.5 g/L)
Hemophagocytosis in bone marrow or spleen or lymph nodes

1
2
3 Low or absent NK activity

4
5 Soluble CD25 (soluble IL-2 receptor (sIL-2R)) $\geq 2,400$ U/mL
6
7
8

9
10 Study Population and eligibility criteria for patients
11
12

13
14 Inclusion criteria:

- 15
16
- 17 • Intensive care patients of at least 18 years old
 - 18 • Suspected or diagnosed HLH: based on HLH-2004 diagnostic criteria
19 (bicytopenia, hyperferritinemia ($\geq 500 \mu\text{g/L}$), fever) or suspicion by the clinicians
20
21
22
23
 - 24 • Eligible to informed consent by the patient himself or the legal representative
25
26
27

28
29 Exclusion criteria:

- 30
31
- 32 • Participation in an interventional study
33
34
 - 35 • Female patients with pregnancy or breastfeeding
36
37

38
39
40 Setting

41
42 Participating ICU include anesthesiological, surgical, medical, neurological, and
43 mixed ICUs. In total, 16 ICUs of the Charité – Universitätsmedizin Berlin will
44 contribute patients.
45
46
47
48
49

50
51
52
53 Objectives and hypotheses

54
55 This study aims to investigate critically ill patients for adult HLH and estimate its
56 incidence rate among suspected patients during ICU stay. Secondly, a panel of
57 various biomarkers candidates from experimental and pediatric studies will be
58
59
60

1
2
3 measured to explore diagnostic potential to diagnose HLH in adult ICU-admitted
4 patients. As a result, HLH might be detected earlier leading to an improved outcome.
5
6
7 Highly sensitive biomarkers may also help to distinguish HLH from sepsis.
8
9

10 11 12 13 Patient and public involvement

14
15 Patients or public were not involved in the development of the research question, the
16 design, the recruitment and the conduct of this study. As a regular medical care, the
17 results of the immunological analyses will be sent to the physicians in charge.
18
19
20
21
22 Patients will be informed of the global results of the study at their request.
23
24
25

26 27 28 Statistical analyses

29
30 Incidence rate of HLH among suspected adult patient during ICU stay will be
31 calculated with 95% confidence intervals. Investigation of potential biomarker will be
32 exploratory. Descriptive statistics between patient groups with confirmed HLH and
33 controls will incorporate mean and standard deviation or absolute and relative
34 frequencies depending on each variable's scale. Uni- and multivariable logistic
35 regression models with confirmed HLH diagnosis as outcome will be calculated for
36 different combinations of influencing variables and biomarkers. Receiver operator
37 characteristic (ROC) analysis will be performed to determine discrimination ability as
38 measured by the area under the curve (AUC) for each continuous biomarker.
39
40 Sensitivity and specificity within our patient sample will be given for cut-off points with
41 highest Youden index. Highly potential markers are found when sensitivity and
42 specificity each reach 90%.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Outcome measures

Primary Endpoint

- Incidence rate of adult HLH among suspected patients during ICU stay

Secondary Endpoints

- Identification of highly sensitive and highly specific biomarkers to safely diagnose adult HLH in ICU
- Trigger and underlying conditions
- Therapy of HLH by clinicians
- ICU and hospital length of stay
- Mortality and survival after 6 months
- Quality of life questionnaire 36-item short form health survey (SF-36) after 6 months [11]
- Human immunodeficiency virus (HIV) antibodies and -antigen
- Epstein Barr Virus (EBV) and Cytomegalovirus (CMV) viral loads
- Inflammatory markers (ferritin, C-reactive protein (CRP), procalcitonin (PCT), interleukin (IL)-1 β , IL-2, IL-6, IL-8, IL-10, IL-18, IL-33, tumor necrosis factor (TNF)- α , interferon (IFN)- γ , sCD25, sCD163, presepsin) [12]
- Perforin and CD107a [13]
- Fibrinogen, triglycerides, bilirubin, lactate dehydrogenase (LDH), liver transaminases (ALAT and ASAT)
- Sodium, serum albumin, serum protein electrophoresis
- Detailed immune status (differential blood count, T cells (CD3+), B cells (CD19+), NK cells (CD16+), T helper cells (CD4+), cytotoxic T cells (CD8+), CD4 / CD8 ratio, HLA-DR of CD8+, CD11a of CD8-, CD57 of CD8-, CD28 of CD8+, HLA-DR of monocytes, CD56bright and CD69 of NK cells)
- Glycosylated ferritin [14] and microRNAs (miR-205-5p, miR-194-5p and miR-30c-5p) [15]
- Chemokines CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL11 (Eotaxin), CCL19, CCL20, CXCL1, CXCL9, CXCL8 (IL-8), CXCL10 (IP-10), CXCL12 (SDF1A) [16]
- HLA Typing

- Biobanking for future research questions (e.g. genetic polymorphisms and gene expression of PRF1, UNC13D, STX11, STXBP2 [7])

Data collection

Number of screened patients, number of patients with suspected HLH who could not be included as well as data on all outcome measures will be collected prospectively.

If the patient received immunosuppressive therapy prior to inclusion, this will be documented separately. Further data including patient demographic data, past medical conditions, physicians' reports and routine laboratory results will be abstracted from the hospital's database. For follow-up six months after study inclusion, patients will be contacted either by telephone or by mail as indicated upon enrolment to assess health-related quality of life and mortality, respectively.

Immunological measurements

Plasma concentrations of soluble IL-2R (sIL-2R or sCD25) will be determined with the IMMULITE™ semi-automatic chemiluminescent immunoassay (Siemens Healthcare GmbH, Erlangen, Germany). Additional soluble factors IL-1 β , IL-2, IL-6, IL-8, IL-10, IL-18, IL-33, TNF- α , IFN- γ will be measured by Meso Scale Discovery® (Meso Scale Diagnostics, Maryland USA). The kit provides all reagents, together with a 96-well plate with specific pre-coated spots, the detection antibodies and assay diluent. The standard will be reconstituted with assay diluent to obtain a lot specific concentration which differs for all cytokines. The vials are inverted multiple times for mixing and, after vortexing, the vials will be kept for 5–10 min at RT and then on ice until use. Preparation of further serial 1:5 dilution of Cytokine Standard is performed. Quality Controls (low and high) are components of the kits and respective Quality

1
2
3 Control ranges are provided by the manufacturer. The Quality Controls (low and high)
4 will be reconstituted with 250 µl of deionized water. The vials are inverted multiple
5 times for mixing and, after vortexing, kept for 5–10 min at RT and then on ice until
6 use. Plasma concentrations of soluble CD163 protein levels from plasma will be
7 determined with the Quantikine® ELISA human CD163 Immunoassay (R&D
8 Systems, Minneapolis, USA). The minimum detectable dose ranged from 0.058-
9 0.613 ng/mL. For measurement of presepsin, Presepsin (Human) ELISA Kit will be
10 used (BioVision, California, USA) with a detection range of 0.156-10 ng/mL.

11
12
13
14
15
16
17
18
19
20
21
22 Flow cytometric analysis of human lymphocyte subsets in EDTA whole blood will be
23 performed, as described recently [17]. Briefly, the following mouse anti-human
24 fluorescently-labelled monoclonal antibodies (mAb) are used for quantification of
25 lymphocytes subsets and analysis of T and NK cell activation markers: cluster of
26 differentiation (CD)3 Allophycocyanine-Alexa Fluor 750 (APC-A750), CD4 energy
27 coupled dye (ECD), CD8 APC, CD11a Fluorescein isothiocyanate (FITC), CD14
28 FITC, CD16 Phycoerythrine (PE), CD19 PE-Cy5.5, CD28 PC5, CD45 Krome-Orange
29 (KrO), CD56 PE or CD56 APC, CD57 Pacific Blue (PB), CD69 PE, HLA-DR PE, (all
30 from Beckman Coulter). Functional analysis of NK cells will be performed using the
31 CD107a degranulation assay according to a protocol published by Bryceson et al.
32 [18]. Briefly, peripheral blood mononuclear cells (PBMC) will be isolated by density
33 gradient centrifugation and incubated overnight in the presence or absence of 3600
34 IU/mL recombinant interleukin-2 (Peprotech). PBMC will then be incubated with the
35 target cell line K562 (ATCC) in a 1:1 ratio for 3 hours. Subsequently, CD107a
36 expression on NK cells is assessed by staining samples with fluorescently-labelled
37 antibodies against lineage markers (see above) and an anti-CD107a FITC-labelled
38 mAb (eBioscience). Perforin expression in NK cells will be assessed by intracellular
39 staining in unstimulated NK cells using the PerFix-nc reagent (Beckman Coulter) for
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 cell permeabilization and an APC-labelled anti-perforin mAb (eBioscience) according
4
5 the manufacturer's instructions.
6
7

8 Expression of human leukocyte antigen-DR (HLA-DR) on monocytes (mHLA-DR) will
9
10 be determined by flow cytometry using a highly standardized quantitative assay, as
11
12 described earlier [19]. In short, whole blood in Vacutainer tubes (BD Biosciences,
13
14 San Jose, CA, USA) containing EDTA are stained with 20 µl of monoclonal
15
16 phycoerythrin-conjugated anti-HLA-DR and PerCP-Cy5.5-conjugated anti-CD14
17
18 antibodies (Quantibrite HLA-DR/monocyte™; BD Biosciences) in the dark at room
19
20 temperature for 30 min. Erythrocyte lysis will be done with 0.5 mL of lysing solution
21
22 (BD Biosciences) for another 30 min at room temperature. Finally, the cells are
23
24 washed with 1 mL PBS buffer containing 2% FCS and analyzed on a Navios flow
25
26 cytometer (Beckman Coulter, Krefeld, Germany). HLA-DR surface expression on
27
28 monocytes will be calculated as monoclonal antibodies bound per cell (mAb/cell)
29
30 using the QuntiBRITE™ PE calibration beads. All flow cytometric analyses will be
31
32 performed on a ten-color Navios flow cytometer using the Navios Software (Beckman
33
34 Coulter). Human glycosylated ferritin will be determined by Enzyme-linked
35
36 Immunosorbent Assay (MyBioSource, San Diego, USA). The sensitivity of this kit is
37
38 2.0 ng/mL.
39
40
41
42
43
44
45

46 The expression of miR-205-5p, miR-194-5p and miR-30c-5p will be determined in
47
48 whole blood, plasma and serum using a protocol published by Balcells et al. [20].
49
50 Briefly, after RNA isolation, miRNAs are polyadenylated and then reverse transcribed
51
52 with a special primer (RT-primer). For quantitative real time PCR (qPCR), two
53
54 specific primers for each miRNA are designed using a software tool from Busk [21].
55
56 All primers are tested for specificity and efficiency. The qPCR will be performed with
57
58 SYBR Green using the QuantStudio5® (Thermo Fisher, Darmstadt, Germany). The
59
60

1
2
3 quantification of chemokines involved in cell trafficking and effector functions of
4 lymphocytes, granulocytes, and mononuclear cells from the CC subfamily (CCL2,
5 CCL3, CCL4, CCL5, CCL11, CCL19, and CCL20) as well as the CXC subfamily
6 (CXCL1, CXCL8 (IL-8), CXCL10, and CXCL12) will be performed with the
7
8 LUNARIS™ Human 11-Plex Chemokine Kit (AYOXXA Biosystems GmbH, Cologne,
9 Germany).

10
11
12 Determination of human leukocyte antigen (HLA) typing will be performed by reverse
13 sequence-specific oligonucleotide (rSSO) assay LABType® (One Lambda, Canoga
14 Park, CA, USA). Typing will be assessed on an intermediate resolution level for HLA-
15 A, -B, -C, -DRB1, -DQA1 and -DQB1. The assay will be performed according to the
16 manufacturer's instructions and data will be acquired on a Luminex® FlexMAP 3D
17 machine (Luminex, Austin, TX, USA).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Informed consent in critically ill patients

36
37 Written informed consent will be obtained from all patients or their legally authorized
38 representatives. Consent for genetic analyzes in future projects will be obtained
39 separately.
40
41
42
43
44
45
46
47

48 Sample size

49
50 The true incidence of adult HLH in ICU is unknown. According to our own research
51 [9] and the annual number of patients admitted to our ICU, we expect to see about
52 200 patients with diagnosed HLH over two years, and about 400 with suspected
53 HLH. Of these, we hope to include at least 100 patients with suspected HLH into the
54 study, of whom about 50 patients are expected to be diagnosed with HLH. When the
55
56
57
58
59
60

1
2
3 sample size is 100, a two-sided 95.0% confidence interval for a single proportion
4
5 using the large sample normal approximation will extend 0.1 from the observed
6
7 proportion for an expected proportion of 0.5 (nQuery Advisor 7.0).
8
9
10

11 12 13 Ethics and Dissemination

14
15
16 The institutional ethics committee approved this study on August 1, 2018
17
18 (EA4/006/18). The data protection commissioner also approved the study (91-SP-
19
20 18), which was registered with clinicaltrials.gov (NCT03510650) on April 27, 2018.
21
22 Results of the study will be disseminated in an international peer-reviewed journal
23
24 and presented at conferences.
25
26
27
28
29
30

31 Discussion

32
33 HLH is a rare condition in adults with poor prognosis. Due to the paucity of data
34
35 available on adult HLH, recognition remains low resulting in delayed diagnosis and
36
37 treatment and finally, fatal outcome. This is the first prospective study to
38
39 systematically investigate routine and non-routine parameters for biomarker
40
41 development. Importantly, the daily systematic screening will help to identify HLH
42
43 patients at an early stage of the syndrome which ultimately will improve patient care,
44
45 patients' safety and outcome. Moreover, describing a distinct pattern of biomarkers
46
47 generates new hypothesis for future research thereby potentially providing targets for
48
49 therapy development. With regard to clinical practice, the HEMICU study seeks to
50
51 inform clinicians about HLH and ICU therapies to improve outcomes for HLH
52
53 patients. However, it is of note that this study does not seek to advice the clinician in
54
55 charge to change therapy. No change in routine management is intended due to the
56
57
58
59
60

1
2
3 observational study design and final decisions are left to the discretion of the
4
5 responsible clinician.
6
7
8
9

10 11 Strengths and Limitations

12
13 This study might be limited in that it only includes ICU patients and findings will not
14
15 be generalizable to non-ICU patients. In addition, patients might have developed
16
17 HLH before ICU admission and will thus be detected and measurements obtained at
18
19 an advanced stage of the disease possibly limiting comparability of the results.
20
21

22
23 Moreover, we will not assess longitudinal parameters preventing us from describing
24
25 dynamics of biomarkers over time. However, as this study aims to develop a tool
26
27 facilitating diagnosis at the earliest possible time point, study endpoints will not be
28
29 affected by lack of repeated measurements. Possible advances of this study include
30
31 comprehensive lab testing of parameters, which have previously been suggested to
32
33 be associated with HLH [12-16]. Previous studies, most of which are retrospective in
34
35 nature, aimed at identifying associations to detect risk factors [2, 22]. Therefore, the
36
37 HEMICU study is the first prospective study of its kind.
38
39
40
41
42
43
44

45 46 Conclusion

47
48 HLH is a life threatening but poorly investigated condition in adult ICU patients. The
49
50 HEMICU study is the first prospective study in adult ICU patients and aims to
51
52 estimate the incidence rate of adult HLH among suspected patients during ICU stay.
53
54 Furthermore, we aim to investigate biomarkers for diagnosis of adult HLH in ICU
55
56 patients. Results of this study will contribute to improved recognition of adult HLH in
57
58 the clinical routine. Potentially earlier diagnosis and thus more effective treatment of
59
60 adult HLH could lead to improved patient outcome. Moreover, our study will provide a

1
2
3 better understanding of adult HLH pathophysiology and the biobanking of DNA,
4
5 plasma and serum will generate a database to investigate future research questions.
6
7
8
9

10 11 Acknowledgements

12
13
14 We thank the Department of Cardiovascular Surgery, the Department of Surgery
15
16 CCM/CVK, the Medical Department, Division of Nephrology and Internal Intensive
17
18 Care Medicine (CVK/CCM), the Medical Department, Division of Infectiology and
19
20 Pneumonology, the Medical Department, Division of Cardiology (CVK), the
21
22 Department of Cardiology (CBF), the Department of Neurology with Experimental
23
24 Neurology, and the Department of Anesthesiology and Operative Intensive Care
25
26 Medicine (CBF) for being part of our study and excellent collaboration. We also thank
27
28 the BIH Biobank Core Facility for support, coordination and storage of blood samples
29
30 (biobank). We are grateful to Dr. Kathrin Scholtz for monitoring the study.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

40 Competing interests

41
42 The authors declare no conflicts of interest.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

48 References

1. Buyse, S., et al., *Critical care management of patients with hemophagocytic lymphohistiocytosis*. Intensive Care Med, 2010. **36**(10): p. 1695-702.
2. Barba, T., et al., *Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study*. Medicine (Baltimore), 2015. **94**(51): p. e2318.
3. Lachmann, G., et al., *[Hemophagocytic lymphohistiocytosis : A diagnostic challenge on the ICU]*. Anaesthesist, 2016. **65**(10): p. 776-786.

- 1
- 2
- 3
4. Devitt, K., et al., *Hemophagocytic lymphohistiocytosis secondary to T-cell/histiocyte-rich large B-cell lymphoma*. *Leuk Res Rep*, 2014. **3**(2): p. 42-5.
5. Filipovich, A.H., *Hemophagocytic lymphohistiocytosis (HLH) and related disorders*. Hematology Am Soc Hematol Educ Program, 2009: p. 127-31.
6. Henter, J.I., et al., *HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis*. *Pediatr Blood Cancer*, 2007. **48**(2): p. 124-31.
7. Ramos-Casals, M., et al., *Adult haemophagocytic syndrome*. *Lancet*, 2014. **383**(9927): p. 1503-1516.
8. Jordan, M.B., et al., *How I treat hemophagocytic lymphohistiocytosis*. *Blood*, 2011. **118**(15): p. 4041-52.
9. Lachmann, G., et al., *Hemophagocytic Lymphohistiocytosis: Potentially Underdiagnosed in Intensive Care Units*. *Shock*, 2018. **50**(2): p. 149-155.
10. Fardet, L., et al., *Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome*. *Arthritis Rheumatol*, 2014. **66**(9): p. 2613-20.
11. Chrispin, P.S., et al., *Short Form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire*. *Anaesthesia*, 1997. **52**(1): p. 15-23.
12. Put, K., et al., *Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma*. *Rheumatology (Oxford)*, 2015. **54**(8): p. 1507-17.
13. Rubin, T.S., et al., *Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH*. *Blood*, 2017. **129**(22): p. 2993-2999.
14. Nabergoj, M., et al., *Diagnostic and prognostic value of low percentage of glycosylated ferritin in acquired hemophagocytic lymphohistiocytosis: A single-center study*. *Int J Lab Hematol*, 2017. **39**(6): p. 620-624.
15. Bay, A., et al., *Evaluation of the plasma micro RNA expression levels in secondary hemophagocytic lymphohistiocytosis*. *Mediterr J Hematol Infect Dis*, 2013. **5**(1): p. e2013066.
16. Bracaglia, C., et al., *Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis*. *Ann Rheum Dis*, 2017. **76**(1): p. 166-172.
17. Klehmet, J., et al., *Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP*. *J Neuroimmunol*, 2015. **283**: p. 17-22.
18. Bryceson, Y.T., et al., *A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes*. *Blood*, 2012. **119**(12): p. 2754-63.
19. Docke, W.D., et al., *Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study*. *Clin Chem*, 2005. **51**(12): p. 2341-7.
20. Balcells, I., S. Cirera, and P.K. Busk, *Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers*. *BMC Biotechnol*, 2011. **11**: p. 70.
21. Busk, P.K., *A tool for design of primers for microRNA-specific quantitative RT-qPCR*. *BMC Bioinformatics*, 2014. **15**: p. 29.
22. Ishii, E., et al., *Nationwide survey of hemophagocytic lymphohistiocytosis in Japan*. *Int J Hematol*, 2007. **86**(1): p. 58-65.

Funding

Gunnar Lachmann is participant of the BIH Charité Clinician Scientist Program granted by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health (BIH). The study is supported by the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité – Universitätsmedizin Berlin.

Authors' contributions

Study concept: GL. Conceived and designed the experiments: GL, CvH, NP, CM, PL, TS, NL, HDV, DK. Performing the experiments: GL, CK, CvH, NP, CM, PN, FSS, GV, FB, NU, UK, NL, LA. Analyzing the data: GL, CK, PN, FSS, SKP, JK, PL, TS. Wrote the manuscript: GL, CK, CvH, NP, CM, SKP, NL, LA, DK. Commented on the manuscript: all authors.

Data statement

Due to legal restrictions imposed by the ethics committee of the Charité – Universitätsmedizin Berlin and the data protection commissioner of the Charité – Universitätsmedizin Berlin, public sharing of study data with other researchers or entities is not allowed. Requests may be sent to dai-researchdata@charite.de.

Figure legends

Figure 1. Screening protocol and blood sampling.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 / Screening protocol and blood sampling.

81x60mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	14
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	14
Protocol version	#3	Date and version identifier	14
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1

1	Roles and	#5b	Name and contact information for the trial sponsor	16
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	16
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating centre,	16
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	Introduction			
24				
25	Background and	#6a	Description of research question and justification for undertaking	5
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30	Background and	#6b	Explanation for choice of comparators	5
31	rationale: choice of			
32	comparators			
33				
34				
35				
36	Objectives	#7	Specific objectives or hypotheses	5
37				
38	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	Methods:			
46	Participants,			
47	interventions, and			
48	outcomes			
49				
50				
51	Study setting	#9	Description of study settings (eg, community clinic, academic	7
52			hospital) and list of countries where data will be collected.	
53			Reference to where list of study sites can be obtained	
54				
55				
56				
57	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	8
58			eligibility criteria for study centres and individuals who will	
59				
60				

perform the interventions (eg, surgeons, psychotherapists)

1			
2			
3	Interventions:	#11a	Interventions for each group with sufficient detail to allow
4	description		replication, including how and when they will be administered
5			
6	Interventions:	#11b	Criteria for discontinuing or modifying allocated interventions for a
7	modifications		given trial participant (eg, drug dose change in response to harms,
8			participant request, or improving / worsening disease)
9			
10			
11	Interventions:	#11c	Strategies to improve adherence to intervention protocols, and any
12	adherence		procedures for monitoring adherence (eg, drug tablet return;
13			laboratory tests)
14			
15			
16	Interventions:	#11d	Relevant concomitant care and interventions that are permitted or
17	concomitant care		prohibited during the trial
18			
19			
20			
21	Outcomes	#12	Primary, secondary, and other outcomes, including the specific
22			measurement variable (eg, systolic blood pressure), analysis metric
23			(eg, change from baseline, final value, time to event), method of
24			aggregation (eg, median, proportion), and time point for each
25			outcome. Explanation of the clinical relevance of chosen efficacy
26			and harm outcomes is strongly recommended
27			
28			
29			
30	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins
31			and washouts), assessments, and visits for participants. A
32			schematic diagram is highly recommended (see Figure)
33			
34			
35			
36	Sample size	#14	Estimated number of participants needed to achieve study
37			objectives and how it was determined, including clinical and
38			statistical assumptions supporting any sample size calculations
39			
40			
41	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach
42			target sample size
43			
44			

**Methods: Assignment
of interventions (for
controlled trials)**

45			
46			
47			
48			
49			
50	Allocation: sequence	#16a	Method of generating the allocation sequence (eg, computer-
51	generation		generated random numbers), and list of any factors for
52			stratification. To reduce predictability of a random sequence,
53			details of any planned restriction (eg, blocking) should be provided
54			in a separate document that is unavailable to those who enrol
55			participants or assign interventions
56			
57			
58			
59			
60			

1	Allocation concealment	#16b	Mechanism of implementing the allocation sequence (eg, central	7
2	mechanism		telephone; sequentially numbered, opaque, sealed envelopes),	
3			describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7				
8	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	7
9	implementation		participants, and who will assign participants to interventions	
10				
11	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial	7
12			participants, care providers, outcome assessors, data analysts), and	
13			how	
14				
15				
16				
17	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is permissible,	7
18	emergency unblinding		and procedure for revealing a participant's allocated intervention	
19			during the trial	
20				
21				
22	Methods: Data			
23	collection,			
24	management, and			
25	analysis			
26				
27				
28				
29	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other	7
30			trial data, including any related processes to promote data quality	
31			(eg, duplicate measurements, training of assessors) and a	
32			description of study instruments (eg, questionnaires, laboratory	
33			tests) along with their reliability and validity, if known. Reference	
34			to where data collection forms can be found, if not in the protocol	
35				
36				
37				
38				
39	Data collection plan:	#18b	Plans to promote participant retention and complete follow-up,	7
40	retention		including list of any outcome data to be collected for participants	
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	#19	Plans for data entry, coding, security, and storage, including any	7
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of data	
47			management procedures can be found, if not in the protocol	
48				
49				
50				
51	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes.	9
52			Reference to where other details of the statistical analysis plan can	
53			be found, if not in the protocol	
54				
55				
56	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and adjusted	9
57	analyses		analyses)	
58				
59				
60				

1	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	9
2	population and missing		adherence (eg, as randomised analysis), and any statistical methods	
3	data		to handle missing data (eg, multiple imputation)	
4				
5				
6	Methods: Monitoring			
7				
8	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary of its	7
9	formal committee		role and reporting structure; statement of whether it is independent	
10			from the sponsor and competing interests; and reference to where	
11			further details about its charter can be found, if not in the protocol.	
12			Alternatively, an explanation of why a DMC is not needed	
13				
14				
15				
16				
17	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	7
18	interim analysis		including who will have access to these interim results and make	
19			the final decision to terminate the trial	
20				
21				
22	Harms	#22	Plans for collecting, assessing, reporting, and managing solicited	7
23			and spontaneously reported adverse events and other unintended	
24			effects of trial interventions or trial conduct	
25				
26				
27	Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and	7
28			whether the process will be independent from investigators and the	
29			sponsor	
30				
31				
32				
33	Ethics and			
34	dissemination			
35				
36				
37	Research ethics	#24	Plans for seeking research ethics committee / institutional review	14
38	approval		board (REC / IRB) approval	
39				
40				
41	Protocol amendments	#25	Plans for communicating important protocol modifications (eg,	14
42			changes to eligibility criteria, outcomes, analyses) to relevant	
43			parties (eg, investigators, REC / IRBs, trial participants, trial	
44			registries, journals, regulators)	
45				
46				
47	Consent or assent	#26a	Who will obtain informed consent or assent from potential trial	14
48			participants or authorised surrogates, and how (see Item 32)	
49				
50				
51	Consent or assent:	#26b	Additional consent provisions for collection and use of participant	14
52	ancillary studies		data and biological specimens in ancillary studies, if applicable	
53				
54				
55	Confidentiality	#27	How personal information about potential and enrolled participants	14
56			will be collected, shared, and maintained in order to protect	
57			confidentiality before, during, and after the trial	
58				
59				
60				

1	Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
2				
3				
4				
5	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	14
6				
7				
8				
9				
10	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	14
11				
12				
13				
14	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14
15				
16				
17				
18				
19				
20				
21	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	14
22				
23				
24	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	14
25				
26				
27				
28	Appendices			
29				
30				
31	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	14
32				
33				
34				
35	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	14
36				
37				
38				
39				

40 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND
 41 3.0. This checklist was completed on 30. June 2019 using <https://www.goodreports.org/>, a tool made by the
 42 [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU): Prospective Observational Study Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032695.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Sep-2019
Complete List of Authors:	<p>Lachmann, Gunnar; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Knaak, Cornelia; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine von Haefen, Clarissa; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Paeschke, Nadine; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Meisel, Christian; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Nyvlt, Peter; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Schuster, Friederike; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Piper, Sophie; Charité Universitätsmedizin Berlin, Institute of Biometry and Clinical Epidemiology Kruppa, Jochen; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany , Institute of Biometry and Clinical Epidemiology Vorderwülbecke, Gerald; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Balzer, Felix; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine La Roseé, Paul; Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Klinik für Innere Medizin II Schenk, Thomas; Universitätsklinikum Jena, Department of Hematology and Oncology Unterwalder, Nadine; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Kölsch, Uwe; Labor Berlin - Charité Vivantes GmbH, Department of Immunology Lachmann, Nils; Charité Universitätsmedizin Berlin, Institute for Transfusion Medicine, H&I Laboratory Akyüz, Levent; Charité Universitätsmedizin Berlin, Institute for Medical Immunology Brunkhorst, Frank; Universitätsklinikum Jena, Center for Clinical Studies, Department of Anesthesiology and Intensive Care Medicine Volk, Hans-Dieter; Charité Universitätsmedizin Berlin, Institute for</p>

	Medical Immunology Keh, Didier; Charité Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine Spies, Claudia; Charité, Universitätsmedizin Berlin, Anaesthesiology
Primary Subject Heading :	Intensive care
Secondary Subject Heading:	Diagnostics, Gastroenterology and hepatology, Haematology (incl blood transfusion), Immunology (including allergy), Rheumatology
Keywords:	Hemophagocytic Lymphohistiocytosis (HLH), Hemophagocytic syndrome (HS), Macrophage activation syndrome (MAS), Sepsis, Biomarker, Intensive Care Unit (ICU)

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU): Prospective Observational Study Protocol

**Gunnar Lachmann^{1,2}, Cornelia Knaak¹, Clarissa von Haefen¹, Nadine Paeschke¹,
Christian Meisel³, Peter Nyvlt¹, Friederike S. Schuster¹, Sophie K. Piper^{2,4},
Jochen Kruppa^{2,4}, Gerald Vorderwülbecke¹, Felix Balzer¹, Paul La Roseé⁵,
Thomas Schenk⁶, Nadine Unterwalder³, Uwe Kölsch³, Nils Lachmann⁷, Levent
Akyüz⁸, Frank M. Brunkhorst⁹, Hans-Dieter Volk⁸, Didier Keh¹, Claudia Spies¹**

¹Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK),
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz
1, D-13353 Berlin, Germany

²Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Str. 2, D-10178 Berlin,
Germany

³Department of Immunology, Labor Berlin - Charité Vivantes GmbH, Sylter Strasse 2,
13353 Berlin

⁴Institute of Biometry and Clinical Epidemiology, Charité – Universitätsmedizin Berlin,
corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and
Berlin Institute of Health, Charitéplatz 1, D-10117 Berlin, Germany

⁵Klinik für Innere Medizin II, Schwarzwald-Baar-Klinikum, Klinikstraße 11, D-78052
Villingen-Schwenningen, Germany

1
2
3 ⁶Department of Hematology and Oncology, Universitätsklinikum Jena,
4 Am Klinikum 1, D-07747 Jena, Germany
5
6

7 ⁷Institute for Transfusion Medicine, H&I Laboratory, Charité – Universitätsmedizin
8 Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin,
9 and Berlin Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany
10
11
12

13 ⁸Institute for Medical Immunology, Charité – Universitätsmedizin Berlin, Corporate
14 Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
15 Institute of Health, Augustenburger Platz 1, D-13353 Berlin, Germany
16
17
18

19 ⁹Center for Clinical Studies, Department of Anesthesiology and Intensive Care
20 Medicine, Universitätsklinikum Jena, Salvador-Allende-Platz 27, D-07747 Jena,
21 Germany
22
23
24
25
26
27

28 Corresponding Author:

29 Dr. med. Gunnar Lachmann

30 Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK)

31 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,

32 Humboldt-Universität zu Berlin, and Berlin Institute of Health

33 Augustenburger Platz 1, D-13353 Berlin, Germany
34
35
36

37 Phone: +49 30 450 551 002

38 Fax: +49 30 450 551 909

39 Email: gunnar.lachmann@charite.de
40
41
42
43
44
45
46

47 **Word and Element Counts**

48
49 Abstract: 412

50
51 Introduction: 553

52
53 Discussion: 433

54
55
56 Figures: 1

57
58
59 Tables: 1
60

Abstract

Introduction: Hemophagocytic Lymphohistiocytosis (HLH) in adults is characterized by toxic immune activation and a sepsis-like syndrome leading to high numbers of undiagnosed cases and mortality rates up to 68%. Early diagnosis and specific immune suppressive treatment is mandatory to avoid fatal outcome, but diagnostic criteria (HLH-2004) are adopted from pediatric HLH, and have not been validated in adults. Experimental studies suggest biomarkers to sufficiently diagnose HLH. However, biomarkers for diagnosis of adult HLH have not been investigated, yet.

Methods and analysis: The Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients study (HEMICU) aims to estimate the incidence rate of adult HLH among suspected adult intensive care unit (ICU) patients. Screening for HLH will be performed in 16 ICUs of the Charité – Universitätsmedizin Berlin. Inclusion criteria are bicytopenia, hyperferritinemia ($\geq 500 \mu\text{g/L}$), fever, or when HLH is suspected by the clinicians. Over a period of two years, we expect inclusion of about 100 patients with suspected HLH. HLH will be diagnosed if at least 5 HLH-2004 criteria are fulfilled together with an expert review, all other included patients will serve as controls. Secondly, a panel of potential biomarker candidates will be explored. DNA, plasma and serum will be stored in a biobank. Primary endpoint of the study is the incidence rate of adult HLH among suspected adult patients during ICU stay. Out of a variety of measured biomarkers, this study furthermore aims to find highly potential biomarkers for diagnosis of adult HLH in ICU. Results of this study will contribute to improved recognition and patient outcome of adult HLH in the clinical routine.

Ethics and dissemination: The institutional ethics committee approved this study on August 1, 2018 (Ethics committee of the Charité – Universitätsmedizin Berlin,

1
2
3 EA4/006/18). Results of the study will be disseminated in an international peer-
4
5 reviewed journal and presented at conferences.
6

7 *Trial registration:* The study was registered with clinicaltrials.gov (NCT03510650) on
8
9 April 27, 2018.
10
11
12

13
14
15 **Keywords:** Hemophagocytic Lymphohistiocytosis (HLH), Hemophagocytic syndrome
16
17 (HS), Macrophage activation syndrome (MAS), sepsis, biomarker, intensive care Unit
18
19 (ICU)
20
21
22

23 24 25 **Strengths and Limitations:** 26

27
28
29 - The HEMICU study is the first prospective study to investigate biomarkers for
30
31 diagnosis of adult HLH in ICU patients.

32
33 - The variety of analyzed biomarkers will also provide a better understanding of adult
34
35 HLH pathophysiology.

36
37 - Biobanking of DNA, plasma and serum of adult HLH patients will generate a
38
39 database to investigate future research questions.

40
41 - This study might be limited in that it only includes ICU patients and findings will not
42
43 be generalizable to non-ICU patients.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory syndrome due to toxic immune activation associated with multiple organ failure and high mortality in intensive care unit (ICU) patients [1-3]. Primary HLH due to genetic causes has been subject of extensive research in pediatric medicine resulting in an advanced understanding of its pathophysiology including identification of underlying genetic defects related to cytotoxic granule exocytosis [4]. However, much less is known about HLH in adults where the secondary form triggered by infections, autoimmune diseases, malignancies or immunosuppressive therapy is more common. Both hereditary primary and reactive secondary HLH are characterized by impaired immune function, i.e. impaired natural-killer (NK) or cytotoxic-T-cell function leading to abnormal activation of cytokine-releasing macrophages and T-cells and finally to an uncontrolled inflammatory condition known as cytokine storm [5].

Currently, diagnosis is based on the HLH-2004 criteria (Table 1) derived from the pediatric HLH-2004 protocol which has not been validated in adult HLH patients [6, 7]. Moreover, diagnosis of HLH in ICU-admitted patients is hampered by its sepsis-like presentation. Clinical features include repetitive fever, hepato- and/or splenomegaly and antibiotic-refractory infections as well as pulmonary and renal involvement with consequent multiple organ failure [7]. Lab findings may reveal cytopenia, hypertriglyceridemia, ferritin $\geq 500 \mu\text{g/L}$, and hypofibrinogenemia. Timely diagnosis is crucial to initiate adequate treatment and thus to improve the prognosis. As demonstrated by Jordan et al. [8], early therapy reduces mortality to 30-35%. However, up to 78% of all HLH cases remain undiagnosed leading to mortality rates as high as 68% [2, 9]. Given the lack of specific diagnostic tests and the established use of invalidated diagnostic criteria in adults, we aim to identify a biomarker panel of high sensitivity and specificity to allow early detection of HLH in critically ill patients.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods and Analysis

Design and screening

Over a two-year period (ongoing since 01/09/2018), screening of all patients admitted to 16 adult ICUs of the Charité - Universitätsmedizin Berlin will be performed. As part of the process, electronic patient charts will be screened daily for bicytopenia by an automated script. All patients with bicytopenia are daily searched by the study team for HLH-2004 criteria (Table 1), the HScore [10], and suspected HLH by the clinicians. If the patient is highly suspicious for HLH, patients will be enrolled after informed consent by the patient himself or the legal representative. Immediately after study enrolment and before initiation of specific HLH treatment, whole blood samples will be obtained for all analyses. Additionally, plasma and serum samples as well as DNA will be stored in a biobank (Figure 1). HLH will be diagnosed if at least 5 HLH-2004 criteria are fulfilled and finally be confirmed after a case-by-case review by two HLH experts. The study aims to include at least 100 patients with suspected HLH. Patients in whom HLH is not confirmed will serve as controls.

Table 1. HLH-2004 diagnostic criteria [6]

HLH-2004 diagnostic criteria of which at least 5 must be fulfilled

Ferritin ≥ 500 $\mu\text{g/L}$

Fever (≥ 38.2 $^{\circ}\text{C}$)

Splenomegaly

Cytopenias in ≥ 2 lines (Hemoglobin < 9 g/dL, platelets < 100 /nL, neutrophils < 1.0 /nL)

Hypertriglyceridemia and/or hypofibrinogenemia

(fasting triglycerides ≥ 265 mg/dL, fibrinogen < 1.5 g/L)

Hemophagocytosis in bone marrow or spleen or lymph nodes

1
2
3 Low or absent NK activity

4
5 Soluble CD25 (soluble IL-2 receptor (sIL-2R)) $\geq 2,400$ U/mL
6
7
8

9
10 Study Population and eligibility criteria for patients
11
12

13
14 Inclusion criteria:

- 15
16
- 17 • Intensive care patients of at least 18 years old
 - 18 • Suspected or diagnosed HLH: based on HLH-2004 diagnostic criteria
19 (bicytopenia, hyperferritinemia ($\geq 500 \mu\text{g/L}$), fever) or suspicion by the clinicians
20
21
22
23
 - 24 • Eligible to informed consent by the patient himself or the legal representative
25
26
27

28
29 Exclusion criteria:

- 30
31
- 32 • Participation in an interventional study
33
34
 - 35 • Female patients with pregnancy or breastfeeding
36
37

38
39
40 Setting

41
42 Participating ICU include anesthesiological, surgical, medical, neurological, and
43 mixed ICUs. In total, 16 ICUs of the Charité – Universitätsmedizin Berlin will
44 contribute patients.
45
46
47
48
49

50
51
52
53 Objectives and hypotheses

54
55 This study aims to investigate critically ill patients for adult HLH and estimate its
56 incidence rate among suspected patients during ICU stay. Secondly, a panel of
57 various biomarkers candidates from experimental and pediatric studies will be
58
59
60

1
2
3 measured to explore diagnostic potential to diagnose HLH in adult ICU-admitted
4 patients. As a result, HLH might be detected earlier leading to an improved outcome.
5
6
7 Highly sensitive biomarkers may also help to distinguish HLH from sepsis.
8
9

10 11 12 13 Patient and public involvement

14
15 Patients or public were not involved in the development of the research question, the
16 design, the recruitment and the conduct of this study. Results of the immunological
17 analyses will be sent to the physicians in charge immediately. Patients will be
18 informed of the global results of the study at their request.
19
20
21
22
23
24
25

26 27 28 Statistical analyses

29
30 Incidence rate of HLH among suspected adult patient during ICU stay will be
31 calculated with 95% confidence intervals. Investigation of potential biomarker will be
32 exploratory. Descriptive statistics between patient groups with confirmed HLH and
33 controls will incorporate mean and standard deviation or absolute and relative
34 frequencies depending on each variable's scale. Uni- and multivariable logistic
35 regression models with confirmed HLH diagnosis as outcome will be calculated for
36 different combinations of influencing variables and biomarkers. Receiver operator
37 characteristic (ROC) analysis will be performed to determine discrimination ability as
38 measured by the area under the curve (AUC) for each continuous biomarker.
39
40 Sensitivity and specificity within our patient sample will be given for cut-off points with
41 highest Youden index. Highly potential markers are found when sensitivity and
42 specificity each reach 90%.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Outcome measures

Primary Endpoint

- Incidence rate of adult HLH among suspected patients during ICU stay

Secondary Endpoints

- Identification of highly sensitive and highly specific biomarkers to safely diagnose adult HLH in ICU
- Trigger and underlying conditions
- Therapy of HLH by clinicians
- ICU and hospital length of stay
- Mortality and survival after 6 months
- Quality of life questionnaire 36-item short form health survey (SF-36) after 6 months [11]
- Human immunodeficiency virus (HIV) antibodies and -antigen
- Epstein Barr Virus (EBV) and Cytomegalovirus (CMV) viral loads
- Inflammatory markers (ferritin, C-reactive protein (CRP), procalcitonin (PCT), interleukin (IL)-1 β , IL-2, IL-6, IL-8, IL-10, IL-18, IL-33, tumor necrosis factor (TNF)- α , interferon (IFN)- γ , sCD25, sCD163, presepsin) [12]
- Perforin and CD107a [13]
- Fibrinogen, triglycerides, bilirubin, lactate dehydrogenase (LDH), liver transaminases (ALAT and ASAT)
- Sodium, serum albumin, serum protein electrophoresis
- Detailed immune status (differential blood count, T cells (CD3+), B cells (CD19+), NK cells (CD16+), T helper cells (CD4+), cytotoxic T cells (CD8+), CD4 / CD8 ratio, HLA-DR of CD8+, CD11a of CD8-, CD57 of CD8-, CD28 of CD8+, HLA-DR of monocytes, CD56bright and CD69 of NK cells)
- Glycosylated ferritin [14] and microRNAs (miR-205-5p, miR-194-5p and miR-30c-5p) [15]
- Chemokines CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL11 (Eotaxin), CCL19, CCL20, CXCL1, CXCL9, CXCL8 (IL-8), CXCL10 (IP-10), CXCL12 (SDF1A) [16]
- HLA Typing

- Biobanking for future research questions (e.g. genetic polymorphisms and gene expression of PRF1, UNC13D, STX11, STXBP2 [7])

Data collection

Number of screened patients, number of patients with suspected HLH who could not be included as well as data on all outcome measures will be collected prospectively.

If the patient received immunosuppressive therapy prior to inclusion, this will be documented separately. Further data including patient demographic data, past medical conditions, physicians' reports and routine laboratory results will be abstracted from the hospital's database. For follow-up six months after study inclusion, patients will be contacted either by telephone or by mail as indicated upon enrolment to assess health-related quality of life and mortality, respectively.

Immunological measurements

Plasma concentrations of soluble IL-2R (sIL-2R or sCD25) will be determined with the IMMULITE™ semi-automatic chemiluminescent immunoassay (Siemens Healthcare GmbH, Erlangen, Germany). Additional soluble factors IL-1 β , IL-2, IL-6, IL-8, IL-10, IL-18, IL-33, TNF- α , IFN- γ will be measured by Meso Scale Discovery® (Meso Scale Diagnostics, Maryland USA). The kit provides all reagents, together with a 96-well plate with specific pre-coated spots, the detection antibodies and assay diluent. The standard will be reconstituted with assay diluent to obtain a lot specific concentration which differs for all cytokines. The vials are inverted multiple times for mixing and, after vortexing, the vials will be kept for 5–10 min at RT and then on ice until use. Preparation of further serial 1:5 dilution of Cytokine Standard is performed. Quality Controls (low and high) are components of the kits and respective Quality

1
2
3 Control ranges are provided by the manufacturer. The Quality Controls (low and high)
4
5 will be reconstituted with 250 µl of deionized water. The vials are inverted multiple
6
7 times for mixing and, after vortexing, kept for 5–10 min at RT and then on ice until
8
9 use. Plasma concentrations of soluble CD163 protein levels from plasma will be
10
11 determined with the Quantikine® ELISA human CD163 Immunoassay (R&D
12
13 Systems, Minneapolis, USA). The minimum detectable dose ranged from 0.058-
14
15 0.613 ng/mL. For measurement of presepsin, Presepsin (Human) ELISA Kit will be
16
17 used (BioVision, California, USA) with a detection range of 0.156-10 ng/mL.
18
19
20
21

22 Flow cytometric analysis of human lymphocyte subsets in EDTA whole blood will be
23
24 performed, as described recently [17]. Briefly, the following mouse anti-human
25
26 fluorescently-labelled monoclonal antibodies (mAb) are used for quantification of
27
28 lymphocytes subsets and analysis of T and NK cell activation markers: cluster of
29
30 differentiation (CD)3 Allophycocyanine-Alexa Fluor 750 (APC-A750), CD4 energy
31
32 coupled dye (ECD), CD8 APC, CD11a Fluorescein isothiocyanate (FITC), CD14
33
34 FITC, CD16 Phycoerythrine (PE), CD19 PE-Cy5.5, CD28 PC5, CD45 Krome-Orange
35
36 (KrO), CD56 PE or CD56 APC, CD57 Pacific Blue (PB), CD69 PE, HLA-DR PE, (all
37
38 from Beckman Coulter). Functional analysis of NK cells will be performed using the
39
40 CD107a degranulation assay according to a protocol published by Bryceson et al.
41
42 [18]. Briefly, peripheral blood mononuclear cells (PBMC) will be isolated by density
43
44 gradient centrifugation and incubated overnight in the presence or absence of 3600
45
46 IU/mL recombinant interleukin-2 (Peprotech). PBMC will then be incubated with the
47
48 target cell line K562 (ATCC) in a 1:1 ratio for 3 hours. Subsequently, CD107a
49
50 expression on NK cells is assessed by staining samples with fluorescently-labelled
51
52 antibodies against lineage markers (see above) and an anti-CD107a FITC-labelled
53
54 mAb (eBioscience). Perforin expression in NK cells will be assessed by intracellular
55
56 staining in unstimulated NK cells using the PerFix-nc reagent (Beckman Coulter) for
57
58
59
60

1
2
3 cell permeabilization and an APC-labelled anti-perforin mAb (eBioscience) according
4
5 the manufacturer's instructions.
6
7

8 Expression of human leukocyte antigen-DR (HLA-DR) on monocytes (mHLA-DR) will
9
10 be determined by flow cytometry using a highly standardized quantitative assay, as
11
12 described earlier [19]. In short, whole blood in Vacutainer tubes (BD Biosciences,
13
14 San Jose, CA, USA) containing EDTA are stained with 20 µl of monoclonal
15
16 phycoerythrin-conjugated anti-HLA-DR and PerCP-Cy5.5-conjugated anti-CD14
17
18 antibodies (Quantibrite HLA-DR/monocyte™; BD Biosciences) in the dark at room
19
20 temperature for 30 min. Erythrocyte lysis will be done with 0.5 mL of lysing solution
21
22 (BD Biosciences) for another 30 min at room temperature. Finally, the cells are
23
24 washed with 1 mL PBS buffer containing 2% FCS and analyzed on a Navios flow
25
26 cytometer (Beckman Coulter, Krefeld, Germany). HLA-DR surface expression on
27
28 monocytes will be calculated as monoclonal antibodies bound per cell (mAb/cell)
29
30 using the QuntiBRITE™ PE calibration beads. All flow cytometric analyses will be
31
32 performed on a ten-color Navios flow cytometer using the Navios Software (Beckman
33
34 Coulter). Human glycosylated ferritin will be determined by Enzyme-linked
35
36 Immunosorbent Assay (MyBioSource, San Diego, USA). The sensitivity of this kit is
37
38 2.0 ng/mL.
39
40
41
42
43
44
45

46 The expression of miR-205-5p, miR-194-5p and miR-30c-5p will be determined in
47
48 whole blood, plasma and serum using a protocol published by Balcells et al. [20].
49
50 Briefly, after RNA isolation, miRNAs are polyadenylated and then reverse transcribed
51
52 with a special primer (RT-primer). For quantitative real time PCR (qPCR), two
53
54 specific primers for each miRNA are designed using a software tool from Busk [21].
55
56 All primers are tested for specificity and efficiency. The qPCR will be performed with
57
58 SYBR Green using the QuantStudio5® (Thermo Fisher, Darmstadt, Germany). The
59
60

1
2
3 quantification of chemokines involved in cell trafficking and effector functions of
4 lymphocytes, granulocytes, and mononuclear cells from the CC subfamily (CCL2,
5 CCL3, CCL4, CCL5, CCL11, CCL19, and CCL20) as well as the CXC subfamily
6 (CXCL1, CXCL8 (IL-8), CXCL10, and CXCL12) will be performed with the
7
8 LUNARIS™ Human 11-Plex Chemokine Kit (AYOXXA Biosystems GmbH, Cologne,
9 Germany).

10
11
12 Determination of human leukocyte antigen (HLA) typing will be performed by reverse
13 sequence-specific oligonucleotide (rSSO) assay LABType® (One Lambda, Canoga
14 Park, CA, USA). Typing will be assessed on an intermediate resolution level for HLA-
15 A, -B, -C, -DRB1, -DQA1 and -DQB1. The assay will be performed according to the
16 manufacturer's instructions and data will be acquired on a Luminex® FlexMAP 3D
17 machine (Luminex, Austin, TX, USA).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 Informed consent in critically ill patients

36
37 Written informed consent will be obtained from all patients or their legally authorized
38 representatives. Consent for genetic analyzes in future projects will be obtained
39 separately.
40
41
42
43
44
45
46
47

48 Sample size

49
50 The true incidence of adult HLH in ICU is unknown. According to our own research
51 [9] and the annual number of patients admitted to our ICU, we expect to see about
52 200 patients with diagnosed HLH over two years, and about 400 with suspected
53 HLH. Of these, we hope to include at least 100 patients with suspected HLH into the
54 study, of whom about 50 patients are expected to be diagnosed with HLH. When the
55
56
57
58
59
60

1
2
3 sample size is 100, a two-sided 95.0% confidence interval for a single proportion
4
5 using the large sample normal approximation will extend 0.1 from the observed
6
7 proportion for an expected proportion of 0.5 (nQuery Advisor 7.0).
8
9

10 11 12 13 Ethics and Dissemination

14
15
16 The institutional ethics committee approved this study on August 1, 2018 (Ethics
17
18 committee of the Charité – Universitätsmedizin Berlin, EA4/006/18). The data
19
20 protection commissioner also approved the study (91-SP-18), which was registered
21
22 with clinicaltrials.gov (NCT03510650) on April 27, 2018. Results of the study will be
23
24 disseminated in an international peer-reviewed journal and presented at conferences.
25
26
27
28
29

30 31 Discussion

32
33
34 HLH is a rare condition in adults with poor prognosis. Due to the paucity of data
35
36 available on adult HLH, recognition remains low resulting in delayed diagnosis and
37
38 treatment and finally, fatal outcome. This is the first prospective study to
39
40 systematically investigate routine and non-routine parameters for biomarker
41
42 development. Importantly, the daily systematic screening will help to identify HLH
43
44 patients at an early stage of the syndrome which ultimately will improve patient care,
45
46 patients' safety and outcome. Moreover, describing a distinct pattern of biomarkers
47
48 generates new hypothesis for future research thereby potentially providing targets for
49
50 therapy development. With regard to clinical practice, the HEMICU study seeks to
51
52 inform clinicians about HLH and ICU therapies to improve outcomes for HLH
53
54 patients. However, it is of note that this study does not seek to advice the clinician in
55
56 charge to change therapy. No change in routine management is intended due to the
57
58
59
60

1
2
3 observational study design and final decisions are left to the discretion of the
4
5 responsible clinician.
6
7
8
9

10 11 Strengths and Limitations

12
13
14 This study might be limited in that it only includes ICU patients and findings will not
15
16 be generalizable to non-ICU patients. In addition, patients might have developed
17
18 HLH before ICU admission and will thus be detected and measurements obtained at
19
20 an advanced stage of the disease possibly limiting comparability of the results.
21
22 Moreover, we will not assess longitudinal parameters preventing us from describing
23
24 dynamics of biomarkers over time. However, as this study aims to develop a tool
25
26 facilitating diagnosis at the earliest possible time point, study endpoints will not be
27
28 affected by lack of repeated measurements. Possible advances of this study include
29
30 comprehensive lab testing of parameters, which have previously been suggested to
31
32 be associated with HLH [12-16]. Previous studies, most of which are retrospective in
33
34 nature, aimed at identifying associations to detect risk factors [2, 22]. Therefore, the
35
36 HEMICU study is the first prospective study of its kind.
37
38
39
40
41
42
43
44
45
46
47
48

49 Acknowledgements

50 We thank the Department of Cardiovascular Surgery, the Department of Surgery
51
52 CCM/CVK, the Medical Department, Division of Nephrology and Internal Intensive
53
54 Care Medicine (CVK/CCM), the Medical Department, Division of Infectiology and
55
56 Pneumonology, the Medical Department, Division of Cardiology (CVK), the
57
58 Department of Cardiology (CBF), the Department of Neurology with Experimental
59
60 Neurology, and the Department of Anesthesiology and Operative Intensive Care

1
2
3 Medicine (CBF) for being part of our study and excellent collaboration. We also thank
4
5 the BIH Biobank Core Facility for support, coordination and storage of blood samples
6
7 (biobank). We are grateful to Dr. Kathrin Scholtz for monitoring the study.
8
9
10
11
12
13

14 Competing interests

15
16
17 The authors declare no conflicts of interest.
18
19
20
21
22

23 References

- 24
25
26
27
28
29 1. Buyse, S., et al., *Critical care management of patients with hemophagocytic lymphohistiocytosis*. Intensive Care Med, 2010. **36**(10): p. 1695-702.
- 30
31 2. Barba, T., et al., *Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study*. Medicine (Baltimore), 2015. **94**(51): p. e2318.
- 32
33 3. Lachmann, G., et al., *[Hemophagocytic lymphohistiocytosis : A diagnostic challenge on the ICU]*. Anaesthetist, 2016. **65**(10): p. 776-786.
- 34
35 4. Devitt, K., et al., *Hemophagocytic lymphohistiocytosis secondary to T-cell/histiocyte-rich large B-cell lymphoma*. Leuk Res Rep, 2014. **3**(2): p. 42-5.
- 36
37 5. Filipovich, A.H., *Hemophagocytic lymphohistiocytosis (HLH) and related disorders*. Hematology Am Soc Hematol Educ Program, 2009: p. 127-31.
- 38
39 6. Henter, J.I., et al., *HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis*. Pediatr Blood Cancer, 2007. **48**(2): p. 124-31.
- 40
41 7. Ramos-Casals, M., et al., *Adult haemophagocytic syndrome*. Lancet, 2014. **383**(9927): p. 1503-1516.
- 42
43 8. Jordan, M.B., et al., *How I treat hemophagocytic lymphohistiocytosis*. Blood, 2011. **118**(15): p. 4041-52.
- 44
45 9. Lachmann, G., et al., *Hemophagocytic Lymphohistiocytosis: Potentially Underdiagnosed in Intensive Care Units*. Shock, 2018. **50**(2): p. 149-155.
- 46
47 10. Fardet, L., et al., *Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome*. Arthritis Rheumatol, 2014. **66**(9): p. 2613-20.
- 48
49 11. Chrispin, P.S., et al., *Short Form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire*. Anaesthesia, 1997. **52**(1): p. 15-23.
- 50
51 12. Put, K., et al., *Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma*. Rheumatology (Oxford), 2015. **54**(8): p. 1507-17.
- 52
53 13. Rubin, T.S., et al., *Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH*. Blood, 2017. **129**(22): p. 2993-2999.
- 54
55 14. Nabergoj, M., et al., *Diagnostic and prognostic value of low percentage of glycosylated ferritin in acquired hemophagocytic lymphohistiocytosis: A single-center study*. Int J Lab Hematol, 2017. **39**(6): p. 620-624.
- 56
57
58
59
60

15. Bay, A., et al., *Evaluation of the plasma micro RNA expression levels in secondary hemophagocytic lymphohistiocytosis*. *Mediterr J Hematol Infect Dis*, 2013. **5**(1): p. e2013066.
16. Bracaglia, C., et al., *Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis*. *Ann Rheum Dis*, 2017. **76**(1): p. 166-172.
17. Klehmet, J., et al., *Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP*. *J Neuroimmunol*, 2015. **283**: p. 17-22.
18. Bryceson, Y.T., et al., *A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes*. *Blood*, 2012. **119**(12): p. 2754-63.
19. Docke, W.D., et al., *Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study*. *Clin Chem*, 2005. **51**(12): p. 2341-7.
20. Balcells, I., S. Cirera, and P.K. Busk, *Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers*. *BMC Biotechnol*, 2011. **11**: p. 70.
21. Busk, P.K., *A tool for design of primers for microRNA-specific quantitative RT-qPCR*. *BMC Bioinformatics*, 2014. **15**: p. 29.
22. Ishii, E., et al., *Nationwide survey of hemophagocytic lymphohistiocytosis in Japan*. *Int J Hematol*, 2007. **86**(1): p. 58-65.

Funding

Gunnar Lachmann is participant of the BIH Charité Clinician Scientist Program granted by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health (BIH). The study is supported by the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité – Universitätsmedizin Berlin.

Authors' contributions

Study concept: GL. Conceived and designed the experiments: GL, CvH, NP, CM, PL, TS, NL, HDV, DK. Performing the experiments: GL, CK, CvH, NP, CM, PN, FSS, GV, FB, NU, UK, NL, LA. Analyzing the data: GL, CK, PN, FSS, SKP, JK, PL, TS. Wrote the manuscript: GL, CK, CvH, NP, CM, SKP, NL, LA, FMB, DK, CS. Commented on the manuscript: all authors.

Data statement

Due to legal restrictions imposed by the ethics committee of the Charité – Universitätsmedizin Berlin and the data protection commissioner of the Charité – Universitätsmedizin Berlin, public sharing of study data with other researchers or entities is not allowed. Requests may be sent to dai-researchdata@charite.de.

Figure legends

Figure 1. Screening protocol and blood sampling.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 / Screening protocol and blood sampling.

81x60mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	14
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	14
Protocol version	#3	Date and version identifier	14
Funding	#4	Sources and types of financial, material, and other support	16
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1

1	Roles and	#5b	Name and contact information for the trial sponsor	16
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	16
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating centre,	16
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	Introduction			
24				
25	Background and	#6a	Description of research question and justification for undertaking	5
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30	Background and	#6b	Explanation for choice of comparators	5
31	rationale: choice of			
32	comparators			
33				
34				
35				
36	Objectives	#7	Specific objectives or hypotheses	5
37				
38	Trial design	#8	Description of trial design including type of trial (eg, parallel	7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	Methods:			
46	Participants,			
47	interventions, and			
48	outcomes			
49				
50				
51	Study setting	#9	Description of study settings (eg, community clinic, academic	7
52			hospital) and list of countries where data will be collected.	
53			Reference to where list of study sites can be obtained	
54				
55				
56				
57	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	8
58			eligibility criteria for study centres and individuals who will	
59				
60				

perform the interventions (eg, surgeons, psychotherapists)

1			
2			
3	Interventions:	#11a	Interventions for each group with sufficient detail to allow
4	description		replication, including how and when they will be administered
5			
6	Interventions:	#11b	Criteria for discontinuing or modifying allocated interventions for a
7	modifications		given trial participant (eg, drug dose change in response to harms,
8			participant request, or improving / worsening disease)
9			
10			
11	Interventions:	#11c	Strategies to improve adherence to intervention protocols, and any
12	adherence		procedures for monitoring adherence (eg, drug tablet return;
13			laboratory tests)
14			
15			
16	Interventions:	#11d	Relevant concomitant care and interventions that are permitted or
17	concomitant care		prohibited during the trial
18			
19			
20			
21	Outcomes	#12	Primary, secondary, and other outcomes, including the specific
22			measurement variable (eg, systolic blood pressure), analysis metric
23			(eg, change from baseline, final value, time to event), method of
24			aggregation (eg, median, proportion), and time point for each
25			outcome. Explanation of the clinical relevance of chosen efficacy
26			and harm outcomes is strongly recommended
27			
28			
29			
30	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins
31			and washouts), assessments, and visits for participants. A
32			schematic diagram is highly recommended (see Figure)
33			
34			
35			
36	Sample size	#14	Estimated number of participants needed to achieve study
37			objectives and how it was determined, including clinical and
38			statistical assumptions supporting any sample size calculations
39			
40			
41	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach
42			target sample size
43			
44			

Methods: Assignment of interventions (for controlled trials)

45			
46			
47			
48			
49			
50	Allocation: sequence	#16a	Method of generating the allocation sequence (eg, computer-
51	generation		generated random numbers), and list of any factors for
52			stratification. To reduce predictability of a random sequence,
53			details of any planned restriction (eg, blocking) should be provided
54			in a separate document that is unavailable to those who enrol
55			participants or assign interventions
56			
57			
58			
59			
60			

1	Allocation concealment	#16b	Mechanism of implementing the allocation sequence (eg, central	7
2	mechanism		telephone; sequentially numbered, opaque, sealed envelopes),	
3			describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7				
8	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	7
9	implementation		participants, and who will assign participants to interventions	
10				
11	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial	7
12			participants, care providers, outcome assessors, data analysts), and	
13			how	
14				
15				
16				
17	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is permissible,	7
18	emergency unblinding		and procedure for revealing a participant's allocated intervention	
19			during the trial	
20				
21				
22	Methods: Data			
23	collection,			
24	management, and			
25	analysis			
26				
27				
28				
29	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other	7
30			trial data, including any related processes to promote data quality	
31			(eg, duplicate measurements, training of assessors) and a	
32			description of study instruments (eg, questionnaires, laboratory	
33			tests) along with their reliability and validity, if known. Reference	
34			to where data collection forms can be found, if not in the protocol	
35				
36				
37				
38				
39	Data collection plan:	#18b	Plans to promote participant retention and complete follow-up,	7
40	retention		including list of any outcome data to be collected for participants	
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	#19	Plans for data entry, coding, security, and storage, including any	7
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of data	
47			management procedures can be found, if not in the protocol	
48				
49				
50				
51	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes.	9
52			Reference to where other details of the statistical analysis plan can	
53			be found, if not in the protocol	
54				
55				
56	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and adjusted	9
57	analyses		analyses)	
58				
59				
60				

1	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	9
2	population and missing		adherence (eg, as randomised analysis), and any statistical methods	
3	data		to handle missing data (eg, multiple imputation)	
4				
5				
6	Methods: Monitoring			
7				
8	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary of its	7
9	formal committee		role and reporting structure; statement of whether it is independent	
10			from the sponsor and competing interests; and reference to where	
11			further details about its charter can be found, if not in the protocol.	
12			Alternatively, an explanation of why a DMC is not needed	
13				
14				
15				
16				
17	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	7
18	interim analysis		including who will have access to these interim results and make	
19			the final decision to terminate the trial	
20				
21				
22	Harms	#22	Plans for collecting, assessing, reporting, and managing solicited	7
23			and spontaneously reported adverse events and other unintended	
24			effects of trial interventions or trial conduct	
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and	7
29			whether the process will be independent from investigators and the	
30			sponsor	
31				
32				
33	Ethics and			
34	dissemination			
35				
36				
37	Research ethics	#24	Plans for seeking research ethics committee / institutional review	14
38	approval		board (REC / IRB) approval	
39				
40				
41	Protocol amendments	#25	Plans for communicating important protocol modifications (eg,	14
42			changes to eligibility criteria, outcomes, analyses) to relevant	
43			parties (eg, investigators, REC / IRBs, trial participants, trial	
44			registries, journals, regulators)	
45				
46				
47	Consent or assent	#26a	Who will obtain informed consent or assent from potential trial	14
48			participants or authorised surrogates, and how (see Item 32)	
49				
50				
51	Consent or assent:	#26b	Additional consent provisions for collection and use of participant	14
52	ancillary studies		data and biological specimens in ancillary studies, if applicable	
53				
54				
55	Confidentiality	#27	How personal information about potential and enrolled participants	14
56			will be collected, shared, and maintained in order to protect	
57			confidentiality before, during, and after the trial	
58				
59				
60				

1	Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
2				
3				
4				
5	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	14
6				
7				
8				
9				
10	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	14
11				
12				
13				
14	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14
15				
16				
17				
18				
19				
20				
21	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	14
22				
23				
24	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	14
25				
26				
27				
28	Appendices			
29				
30				
31	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	14
32				
33				
34	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	14
35				
36				
37				
38				
39				

40 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND
 41 3.0. This checklist was completed on 30. June 2019 using <https://www.goodreports.org/>, a tool made by the
 42 [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60